https://trial.medpath.com/news/star-therapeutics-secures-125m-series-d-to-advance-von-willebrand-disease-drug-vga039-through-phase-3-testing 2025-09-30T13:14:42+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-cuts-workforce-by-50-following-fda-rejection-of-cancer-drug-application 2025-09-30T13:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-ren-based-migraine-wearable-device-opening-new-treatment-pathway-for-130-million-patients 2025-09-30T13:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/acurx-receives-ema-approval-for-pediatric-investigation-plan-for-ibezapolstat-in-c-difficile-infection 2025-09-30T13:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-cs-1103-for-methamphetamine-overdose-treatment 2025-09-30T13:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharmaceutical-submits-cenobamate-application-in-japan-following-successful-phase-3-trial 2025-09-30T13:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/orion-discontinues-odm-105-development-after-phase-2-insomnia-trial-fails-to-meet-primary-endpoints 2025-09-30T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-specific-mhc-ii-expression-emerges-as-predictive-biomarker-for-immunotherapy-response-in-triple-negative-breast-cancer 2025-09-30T09:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/vicore-pharma-s-buloxibutid-receives-orphan-drug-designation-in-japan-for-idiopathic-pulmonary-fibrosis-treatment 2025-09-30T09:14:05+00:00 hourly 0.9 https://trial.medpath.com/news/wockhardt-s-nafithromycin-faces-nppa-pricing-exemption-hurdle-over-patent-validity-questions 2025-09-30T09:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-bart-trial-shows-adjuvant-radiation-therapy-significantly-reduces-pelvic-recurrence-in-high-risk-bladder-cancer 2025-09-30T05:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/sugemalimab-plus-chemotherapy-shows-clinical-promise-but-lacks-cost-effectiveness-in-advanced-gastric-cancer 2025-09-30T05:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/novel-alzheimer-s-drug-thn391-targets-fibrin-protein-in-first-in-human-trial 2025-09-30T05:14:33+00:00 hourly 0.9 https://trial.medpath.com/news/full-life-technologies-secures-77-million-series-c-to-advance-radiopharmaceutical-pipeline-and-manufacturing 2025-09-30T05:14:28+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-secures-patent-protection-for-bioengineered-esophagus-through-2041 2025-09-30T05:13:59+00:00 hourly 0.9 https://trial.medpath.com/news/dimerix-s-dmx-200-receives-orphan-drug-designation-in-japan-for-rare-kidney-disease-treatment 2025-09-30T05:13:57+00:00 hourly 0.9 https://trial.medpath.com/news/novocure-s-ttfields-therapy-significantly-delays-brain-metastasis-progression-in-nsclc-patients-following-stereotactic-radiosurgery 2025-09-30T05:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/remote-monitoring-reduces-pediatric-asthma-hospitalizations-by-58-in-dutch-multicentre-study 2025-09-30T01:20:43+00:00 hourly 0.9 https://trial.medpath.com/news/anaptysbio-plans-corporate-split-to-separate-royalty-assets-from-drug-development-operations 2025-09-30T01:18:41+00:00 hourly 0.9 https://trial.medpath.com/news/danicamtiv-shows-promise-in-phase-2a-trial-for-genetic-dilated-cardiomyopathy 2025-09-30T01:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/sutro-biopharma-cuts-33-of-workforce-to-extend-cash-runway-through-adc-development-milestones 2025-09-30T01:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/biodegradable-brain-implants-show-promise-in-preventing-glioblastoma-recurrence-through-immune-system-reprogramming 2025-09-30T01:14:50+00:00 hourly 0.9 https://trial.medpath.com/news/led-based-photobiomodulation-device-shows-70-reduction-in-severe-oral-mucositis-for-head-and-neck-cancer-patients 2025-09-30T01:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-shows-five-treatment-radiation-regimen-improves-quality-of-life-for-prostate-cancer-patients 2025-09-30T01:14:45+00:00 hourly 0.9 https://trial.medpath.com/news/ars-pharmaceuticals-secures-250-million-loan-facility-to-accelerate-neffy-commercialization 2025-09-30T01:14:27+00:00 hourly 0.9 https://trial.medpath.com/news/septerna-appoints-keith-gottesdiener-as-board-director-and-r-d-committee-chair 2025-09-30T01:13:07+00:00 hourly 0.9 https://trial.medpath.com/news/locus-cell-secures-first-international-phase-iii-cdmo-partnership-with-cambium-bio-for-dry-eye-therapy 2025-09-30T01:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/outlook-surgical-receives-fda-510-k-clearance-for-revolutionary-hybrid-endoscope-system 2025-09-30T01:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-new-rmat-guidance-to-accelerate-regenerative-medicine-development 2025-09-30T01:12:48+00:00 hourly 0.9 https://trial.medpath.com/news/gammacore-non-invasive-vagus-nerve-stimulation-shows-promise-for-persistent-post-concussion-symptoms-in-102-patient-study 2025-09-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-director-criticizes-lupus-nephritis-drug-lupkynis-questions-surrogate-endpoint-approvals 2025-09-29T21:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/conflicting-results-emerge-from-two-major-trials-comparing-proton-beam-therapy-to-imrt-for-head-and-neck-cancer 2025-09-29T21:15:31+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-adebrelimab-efficacy-in-extensive-stage-small-cell-lung-cancer 2025-09-29T21:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/chlorate-antibiotic-combination-shows-10000-fold-increase-in-efficacy-against-chronic-wound-infections 2025-09-29T21:14:24+00:00 hourly 0.9 https://trial.medpath.com/news/jr-446-receives-japanese-orphan-drug-designation-for-rare-sanfilippo-syndrome-type-b 2025-09-29T21:13:45+00:00 hourly 0.9 https://trial.medpath.com/news/tae-life-sciences-demonstrates-enhanced-tumor-control-with-novel-bnct-immunotherapy-combination-in-preclinical-studies 2025-09-29T21:13:43+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-shows-promise-for-probiotic-bl21-in-preventing-radiation-induced-enteritis 2025-09-29T21:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/accendatech-initiates-phase-3-trial-of-act001-for-small-cell-lung-cancer-with-brain-metastasis 2025-09-29T21:12:19+00:00 hourly 0.9 https://trial.medpath.com/news/angiosafe-s-santreva-atk-receives-fda-clearance-for-peripheral-artery-disease-treatment 2025-09-29T21:11:51+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-based-drug-shows-significant-pain-relief-in-large-clinical-trial-for-chronic-lower-back-pain 2025-09-29T21:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/affluent-medical-s-artus-robotic-urinary-sphincter-shows-87-improvement-in-pilot-trial-results 2025-09-29T21:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-s-sonelokimab-shows-promise-in-teen-hs-patients-despite-adult-trial-setbacks 2025-09-29T21:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-therapeutics-reports-promising-results-for-certepetide-in-pancreatic-cancer-trial 2025-09-29T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/aarvik-therapeutics-secures-series-seed-2-funding-to-advance-next-generation-adc-platform 2025-09-29T17:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-sciences-secures-exclusive-global-rights-to-first-in-class-p-glycoprotein-inhibitor-encequidar 2025-09-29T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/gi-innovation-receives-fda-fast-track-designation-for-gi-102-melanoma-therapy 2025-09-29T17:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/iqure-pharma-secures-us-patent-for-first-in-class-cns-drug-iq-007-targeting-glutamate-excitotoxicity 2025-09-29T17:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trilynx-trial-shows-xevinapant-worsens-outcomes-in-head-and-neck-cancer-patients 2025-09-29T17:21:38+00:00 hourly 0.9 https://trial.medpath.com/news/vascarta-completes-phase-1-trial-of-topical-curcumin-gel-vas-101-for-knee-osteoarthritis 2025-09-29T17:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-appoints-alan-sandler-as-chief-development-officer-to-advance-ras-targeted-cancer-pipeline 2025-09-29T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/rigel-pharmaceuticals-reports-strong-growth-across-oncology-portfolio-with-44-revenue-increase 2025-09-29T17:21:12+00:00 hourly 0.9 https://trial.medpath.com/news/predictive-oncology-secures-343-5-million-to-launch-world-s-first-strategic-compute-reserve-for-ai-drug-discovery 2025-09-29T17:20:59+00:00 hourly 0.9 https://trial.medpath.com/news/provectus-biopharmaceuticals-launches-preclinical-study-of-oral-pv-10-for-bladder-cancer-treatment 2025-09-29T17:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/cue-biopharma-appoints-dr-usman-azam-as-ceo-pivots-to-autoimmune-disease-focus-with-cue-401 2025-09-29T17:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/xenopax-demonstrates-superior-efficacy-in-steroid-refractory-acute-gvhd-treatment 2025-09-29T17:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/rome-trial-demonstrates-precision-oncology-benefits-in-advanced-solid-tumors 2025-09-29T17:17:05+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-shows-cannabis-extract-ver-01-delivers-significant-pain-relief-for-chronic-low-back-pain 2025-09-29T17:16:59+00:00 hourly 0.9 https://trial.medpath.com/news/cormedix-completes-phase-iii-enrollment-for-rezzayo-antifungal-prophylaxis-in-bone-marrow-transplant-patients 2025-09-29T17:16:24+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-therapeutics-appoints-andrew-bayliffe-as-chief-development-officer-to-advance-somatic-genomics-platform 2025-09-29T17:14:34+00:00 hourly 0.9 https://trial.medpath.com/news/tabuk-launches-vibativ-antibiotic-in-saudi-arabia-to-combat-multidrug-resistant-infections 2025-09-29T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/zurnai-auto-injector-shows-superior-performance-over-intranasal-naloxone-in-fentanyl-overdose-reversal-study 2025-09-29T17:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/rezon-bio-launches-as-european-cdmo-for-biologics-with-dual-facility-operations-in-poland 2025-09-29T17:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-launches-direct-to-patient-platform-for-cosentyx-with-55-discount-in-us 2025-09-29T17:12:25+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-resubmits-fda-application-for-first-once-weekly-insulin-for-type-2-diabetes 2025-09-29T17:11:36+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-to-launch-ovarian-cancer-drug-elahere-in-uk-at-us-list-price 2025-09-29T17:11:11+00:00 hourly 0.9 https://trial.medpath.com/news/climb-bio-s-clym116-shows-superior-performance-in-iga-nephropathy-preclinical-study 2025-09-29T13:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-radiation-therapy-shows-promise-for-knee-osteoarthritis-pain-relief-in-clinical-trial 2025-09-29T13:19:34+00:00 hourly 0.9 https://trial.medpath.com/news/recode-therapeutics-secures-29m-financing-to-advance-inhaled-mrna-therapy-for-cystic-fibrosis 2025-09-29T13:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-s-sonelokimab-falls-short-in-hidradenitis-suppurativa-trials-shares-plummet-80 2025-09-29T13:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/dogwood-therapeutics-secures-exclusive-license-for-sp16-cancer-pain-treatment-with-nci-funded-phase-1b-trial 2025-09-29T13:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/redx-pharma-s-zelasudil-shows-promise-in-phase-2a-ipf-trial-with-47-reduction-in-lung-function-decline 2025-09-29T13:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-advances-tnx-2900-to-phase-2-trial-for-prader-willi-syndrome-following-fda-clearance 2025-09-29T13:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/oxccu-raises-28m-series-b-to-scale-sustainable-aviation-fuel-technology-from-waste-carbon 2025-09-29T13:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/mannkind-appoints-dr-ajay-ahuja-as-chief-medical-officer-to-advance-inhaled-therapeutics-pipeline 2025-09-29T13:14:49+00:00 hourly 0.9 https://trial.medpath.com/news/rapt-therapeutics-receives-fda-clearance-to-advance-rpt904-phase-2b-trial-for-food-allergy-treatment 2025-09-29T13:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/kedrion-biopharma-secures-fda-approval-for-qivigy-first-proprietary-ivig-therapy-for-primary-immunodeficiency 2025-09-29T13:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-acquires-visufarma-for-eur190-million-to-expand-european-ophthalmology-portfolio 2025-09-29T09:22:53+00:00 hourly 0.9 https://trial.medpath.com/news/virometix-completes-enrollment-in-phase-i-trial-of-v-212-synthetic-pneumococcal-vaccine 2025-09-29T09:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/dinamiqs-opens-switzerland-s-first-cgmp-viral-vector-manufacturing-facility-partners-with-seal-therapeutics-for-muscular-dystrophy-gene-therapy 2025-09-29T09:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-ceo-emma-walmsley-to-step-down-luke-miels-named-successor 2025-09-29T09:18:59+00:00 hourly 0.9 https://trial.medpath.com/news/clinuvel-advances-novel-sustained-release-peptide-formulations-to-preclinical-testing 2025-09-29T09:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-accepts-nda-for-dorzagliatin-world-s-first-glucokinase-activator-for-type-2-diabetes 2025-09-29T09:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/agentic-ai-poised-to-transform-pharmaceutical-r-d-through-autonomous-multi-agent-systems 2025-09-29T08:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-reports-phase-3-teton-2-trial-results-in-conference-call 2025-09-29T01:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/pam50-biomarker-predicts-hormone-therapy-benefit-in-recurrent-prostate-cancer-balance-trial-shows 2025-09-29T01:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-announces-5-2-billion-acquisition-of-merus-to-expand-late-stage-oncology-pipeline 2025-09-29T01:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/first-predictive-biomarker-for-hormone-therapy-in-recurrent-prostate-cancer-validated-in-phase-ii-balance-trial 2025-09-29T01:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/beta-technologies-files-for-825-million-ipo-to-fund-electric-aircraft-development 2025-09-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/leo-cancer-care-unveils-gracetm-first-upright-photon-therapy-system-at-astro-2025 2025-09-28T21:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/vision-preserving-uveal-melanoma-treatment-shows-unexpected-survival-benefits-in-ucla-study 2025-09-28T21:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-s-sonelokimab-shows-mixed-results-in-phase-3-hidradenitis-suppurativa-trials 2025-09-28T17:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/altesa-biosciences-vapendavir-shows-promise-in-copd-rhinovirus-challenge-study 2025-09-28T17:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-pharmaceuticals-advances-ai-powered-cancer-drug-rec-617-to-phase-2-trial-despite-high-risk-profile 2025-09-28T17:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/uniqure-s-huntington-s-disease-gene-therapy-shows-75-reduction-in-disease-progression-pressures-ptc-therapeutics 2025-09-28T13:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/combination-inhaler-reduces-asthma-attacks-in-children-by-45-in-landmark-trial 2025-09-28T09:12:44+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-launches-bioinsight-ai-unit-and-expands-kras-companion-diagnostic-partnerships 2025-09-28T09:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/ruxolitinib-cream-achieves-positive-phase-3-results-for-atopic-dermatitis-in-china 2025-09-28T09:11:25+00:00 hourly 0.9 https://trial.medpath.com/news/gossamer-bio-secures-option-to-acquire-first-in-class-on-demand-pulmonary-hypertension-therapy-rt234 2025-09-28T01:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/bio-techne-expands-oxford-nanopore-partnership-through-2032-for-advanced-genetic-diagnostics 2025-09-28T01:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/carnegie-mellon-develops-living-microbots-from-human-lung-cells-for-targeted-drug-delivery 2025-09-28T01:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/ionis-pharmaceuticals-stock-surges-85-following-strong-performance-in-gene-targeted-therapies 2025-09-28T01:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/clearpoint-neuro-appoints-dr-paul-larson-as-chief-medical-officer-and-unveils-robotic-neuro-navigation-system 2025-09-27T21:11:15+00:00 hourly 0.9 https://trial.medpath.com/news/genomic-tool-enables-personalized-radiation-dosing-for-hpv-positive-throat-cancer 2025-09-27T21:10:44+00:00 hourly 0.9 https://trial.medpath.com/news/vidofludimus-calcium-shows-promise-for-progressive-ms-despite-missing-primary-endpoint-in-phase-2-trial 2025-09-27T17:12:10+00:00 hourly 0.9 https://trial.medpath.com/news/stream-program-delivers-actionable-genomic-insights-for-59-of-pediatric-cancer-patients-in-asia-s-first-nationwide-wgs-initiative 2025-09-27T17:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/pepgen-raises-115-million-to-advance-oligonucleotide-therapies-for-neuromuscular-diseases 2025-09-27T17:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/dmt-shows-neuroprotective-effects-in-stroke-through-blood-brain-barrier-stabilization-and-anti-inflammatory-action 2025-09-27T13:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/shape-therapeutics-to-present-novel-aav5-capsid-and-alpha-synuclein-targeting-therapy-for-parkinson-s-disease-at-esgct-congress 2025-09-27T09:12:29+00:00 hourly 0.9 https://trial.medpath.com/news/amalee-trial-shows-400mg-ribociclib-dose-fails-to-match-600mg-efficacy-in-advanced-breast-cancer 2025-09-27T09:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/newcastle-university-researchers-develop-first-targeted-therapy-for-rare-kidney-disease-c3g 2025-09-27T09:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/soligenix-raises-7-5-million-in-public-offering-to-advance-rare-disease-pipeline 2025-09-27T05:11:39+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-expands-35-monthly-insulin-program-to-all-americans-regardless-of-insurance-status 2025-09-27T01:22:08+00:00 hourly 0.9 https://trial.medpath.com/news/factor-bioscience-sues-astrazeneca-and-cellectis-over-gene-editing-patent-infringement 2025-09-27T01:18:33+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-lipid-nanoparticles-show-promise-for-non-surgical-cataract-treatment-in-rat-studies 2025-09-27T01:18:30+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-launches-direct-to-consumer-platform-offering-up-to-70-discounts-on-key-medications 2025-09-27T01:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/apixaban-shows-superior-safety-profile-compared-to-rivaroxaban-in-cancer-associated-venous-thromboembolism 2025-09-27T01:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-cincinnati-researchers-develop-novel-drug-targeting-hsp70-for-pancreatic-cancer-treatment 2025-09-27T01:15:14+00:00 hourly 0.9 https://trial.medpath.com/news/new-antibiotic-approval-pathways-balance-urgent-medical-need-with-limited-clinical-data 2025-09-27T01:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/pepgen-s-dm1-therapy-achieves-record-53-7-splicing-correction-in-phase-1-trial 2025-09-26T17:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-launches-direct-to-consumer-platform-with-up-to-70-drug-discounts-following-trump-administration-pressure 2025-09-26T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/novel-t-cell-receptor-therapy-targets-ctnnb1-mutation-achieves-complete-tumor-clearance-in-preclinical-studies 2025-09-26T17:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/isth0036-shows-unexpected-anti-fibrotic-and-visual-benefits-in-phase-2a-retinal-disease-trial 2025-09-26T17:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/predict-rt-trial-completes-enrollment-testing-genomic-guided-treatment-strategies-for-high-risk-prostate-cancer 2025-09-26T17:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-submits-bla-for-omalizumab-biosimilar-to-challenge-4-1-billion-xolair-market 2025-09-26T17:15:58+00:00 hourly 0.9 https://trial.medpath.com/news/me-therapeutics-secures-u-s-patent-for-g-csf-antibody-cancer-therapy-and-advances-multi-platform-pipeline 2025-09-26T17:15:50+00:00 hourly 0.9 https://trial.medpath.com/news/nigeria-partners-with-china-to-establish-africa-s-first-local-insulin-production-facility 2025-09-26T17:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/kerry-inaugurates-leipzig-biotechnology-centre-to-advance-pharmaceutical-and-food-applications 2025-09-26T17:14:29+00:00 hourly 0.9 https://trial.medpath.com/news/harrow-acquires-melt-pharmaceuticals-to-advance-non-opioid-sedation-therapy-melt-300 2025-09-26T13:16:52+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-trial-shows-promise-for-ms-myelin-repair-using-diabetes-drug-antihistamine-combination 2025-09-26T13:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/who-supported-study-reveals-covid-19-vaccine-effectiveness-among-egyptian-healthcare-workers-during-omicron-era 2025-09-26T13:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/trump-s-100-tariffs-on-branded-pharmaceuticals-trigger-sharp-decline-in-indian-pharma-stocks 2025-09-26T13:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/swissmedic-approves-two-orphan-drugs-for-rare-cancers-ayvakyt-for-gist-and-mastocytosis-vanflyta-for-flt3-itd-aml 2025-09-26T13:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/deep-eigenmatics-receives-us-patent-for-ai-driven-protein-design-method-in-drug-discovery 2025-09-26T13:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/concept-life-sciences-establishes-one-of-uk-s-largest-drug-discovery-research-sites-with-major-facility-expansion 2025-09-26T13:13:35+00:00 hourly 0.9 https://trial.medpath.com/news/electra-battery-materials-secures-30-million-financing-for-north-america-s-first-cobalt-sulfate-refinery 2025-09-26T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lancet-study-confirms-rabishield-monoclonal-antibody-therapy-as-safe-effective-alternative-for-rabies-prevention 2025-09-26T09:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/first-successful-car-t-cell-therapy-for-multidrug-resistant-ulcerative-colitis-achieves-complete-remission 2025-09-26T09:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/cayman-chemical-partners-with-akadeum-to-distribute-revolutionary-microbubble-cell-isolation-technology 2025-09-26T09:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/zimmer-biomet-receives-world-s-first-pmda-approval-for-iodine-treated-hip-replacement-system 2025-09-26T09:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/roche-presents-complete-tigit-failure-data-at-esmo-2025-revealing-costly-misstep-in-cancer-immunotherapy 2025-09-26T09:20:17+00:00 hourly 0.9 https://trial.medpath.com/news/cadence-launches-rocs-x-ai-platform-for-drug-discovery-enabling-trillion-molecule-virtual-screening 2025-09-26T09:20:14+00:00 hourly 0.9 https://trial.medpath.com/news/inoviq-secures-exclusive-global-rights-to-university-of-queensland-s-ovarian-cancer-biomarker-technology 2025-09-26T05:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-canada-partners-with-mint-pharmaceuticals-for-adalat-xl-distribution-to-strengthen-canadian-market-access 2025-09-26T01:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/organogenesis-renu-fails-to-meet-primary-endpoint-in-second-phase-3-trial-for-knee-osteoarthritis 2025-09-26T01:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/uk-extends-vpag-2026-decision-deadline-to-november-14-amid-life-sciences-uncertainty 2025-09-26T01:28:35+00:00 hourly 0.9 https://trial.medpath.com/news/anebulo-pharmaceuticals-initiates-phase-i-trial-of-iv-selonabant-as-first-cannabis-toxicity-antidote 2025-09-26T01:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/n2off-stockholders-approve-acquisition-of-mitocarex-bio-targeting-mitochondrial-slc25-proteins-for-cancer-therapy 2025-09-26T01:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/bullfrog-ai-and-sygnature-discovery-launch-commercial-sales-of-ai-powered-drug-discovery-platform 2025-09-26T01:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/onconetix-and-ocuvex-terminate-merger-agreement-as-ocuvex-prepares-omlonti-commercial-launch 2025-09-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tae-life-sciences-partners-with-university-of-wisconsin-madison-to-launch-first-us-accelerator-based-bnct-cancer-treatment-center 2025-09-25T22:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/hitachi-high-tech-partners-with-elitech-to-develop-automated-pcr-platform-for-infectious-disease-testing 2025-09-25T22:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/uc-irvine-researchers-develop-pan-cancer-immunotherapy-using-velcro-like-glycan-targeting-technology 2025-09-25T22:18:37+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-doctors-pioneer-car-t-cell-therapy-for-severe-lupus-in-regional-first 2025-09-25T22:16:36+00:00 hourly 0.9 https://trial.medpath.com/news/mediwound-s-nexobrid-receives-marketing-authorization-in-australia-expanding-global-burn-treatment-access 2025-09-25T22:14:50+00:00 hourly 0.9 https://trial.medpath.com/news/kardigan-secures-254-million-series-b-to-advance-three-late-stage-cardiovascular-programs 2025-09-25T22:14:28+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-reports-positive-phase-iii-confides-trial-results-for-highly-sensitized-kidney-transplant-patients 2025-09-25T20:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/esmo-2025-showcases-promising-first-in-human-data-for-kras-g12c-and-fgfr3-inhibitors 2025-09-25T20:20:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-first-spectacle-lens-to-slow-myopia-progression-in-children 2025-09-25T20:19:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-removes-rems-program-for-vandetanib-in-medullary-thyroid-cancer-after-decade-of-safe-use 2025-09-25T20:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/clean-food-group-acquires-million-liter-fermentation-facility-to-scale-sustainable-oil-production 2025-09-25T20:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/apiject-submits-first-of-kind-prefilled-plastic-injection-device-to-fda-for-approval 2025-09-25T20:18:38+00:00 hourly 0.9 https://trial.medpath.com/news/qurient-and-synaffix-partner-to-develop-first-in-class-cdk7-dual-payload-adc-for-refractory-cancers 2025-09-25T20:18:28+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-miami-enrolls-first-patients-in-pivotal-trial-testing-ai-powered-spine-pain-diagnostic-technology 2025-09-25T19:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/generate-biomedicines-advances-ai-engineered-asthma-antibody-gb-0895-to-phase-3-trials-with-six-month-dosing-interval 2025-09-25T19:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/aim-immunotech-secures-japanese-patent-for-ampligen-combination-therapy-in-oncology-through-2039 2025-09-25T19:01:07+00:00 hourly 0.9 https://trial.medpath.com/news/german-federal-patent-court-upholds-newron-s-xadago-patent-for-parkinson-s-disease-treatment 2025-09-25T19:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/verismo-therapeutics-partners-with-miltenyi-biotec-to-advance-kir-car-platform-for-solid-tumor-treatment 2025-09-25T19:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/poolbeg-pharma-advances-polb-001-phase-2a-trial-to-prevent-cytokine-release-syndrome-in-multiple-myeloma 2025-09-25T19:00:02+00:00 hourly 0.9 https://trial.medpath.com/news/ac-immune-s-tau-targeting-immunotherapy-achieves-94-100-response-rate-in-alzheimer-s-phase-1b-2a-trial 2025-09-25T18:59:56+00:00 hourly 0.9 https://trial.medpath.com/news/aspen-neuroscience-advances-commercial-ready-parkinson-s-cell-therapy-in-phase-1-2a-trial 2025-09-25T18:59:36+00:00 hourly 0.9 https://trial.medpath.com/news/bambusa-therapeutics-advances-bbt001-bispecific-antibody-to-patient-testing-following-promising-healthy-volunteer-data 2025-09-25T18:59:30+00:00 hourly 0.9 https://trial.medpath.com/news/clearnote-health-receives-uk-regulatory-approval-for-multi-cancer-detection-tests 2025-09-25T18:59:21+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-2-trial-shows-promise-for-gut-microbiome-therapy-combined-with-immunotherapy-in-advanced-cancers 2025-09-25T18:58:49+00:00 hourly 0.9 https://trial.medpath.com/news/nih-awards-15-6-million-to-advance-research-on-rare-bone-and-metabolic-disorders 2025-09-25T18:58:43+00:00 hourly 0.9 https://trial.medpath.com/news/evaxion-out-licenses-ai-discovered-vaccine-candidate-evx-b3-to-merck-for-7-5m-upfront-592m-in-milestones 2025-09-25T18:57:52+00:00 hourly 0.9 https://trial.medpath.com/news/tiziana-life-sciences-advances-il-6-receptor-antibody-tzls-501-following-novartis-1-4b-tourmaline-acquisition 2025-09-25T18:57:13+00:00 hourly 0.9 https://trial.medpath.com/news/lunai-bioworks-advances-ai-powered-parkinson-s-biomarker-discovery-program-for-strategic-pharma-partnerships 2025-09-25T18:56:24+00:00 hourly 0.9 https://trial.medpath.com/news/recode-precision-medicine-protocol-shows-dual-benefits-for-cognitive-decline-and-depression 2025-09-25T18:55:50+00:00 hourly 0.9 https://trial.medpath.com/news/quantoom-biosciences-partners-with-memorial-sloan-kettering-to-advance-personalized-rna-cancer-therapies 2025-09-25T18:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/scisparc-launches-quantum-computing-initiative-to-revolutionize-3d-protein-modeling-for-drug-discovery 2025-09-25T18:55:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-third-orphan-drug-designation-to-biostar-s-utidelone-for-pancreatic-cancer-treatment 2025-09-25T18:54:28+00:00 hourly 0.9 https://trial.medpath.com/news/axon-therapies-secures-32m-series-a-to-advance-novel-heart-failure-treatment-through-sympathetic-nervous-system-ablation 2025-09-25T18:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/sparrow-pharmaceuticals-secures-95-million-series-b-to-advance-novel-diabetes-treatment-targeting-elevated-cortisol 2025-09-25T13:16:20+00:00 hourly 0.9 https://trial.medpath.com/news/leap-therapeutics-to-present-final-defiance-phase-2-results-for-sirexatamab-in-advanced-colorectal-cancer-at-esmo-2025 2025-09-25T13:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-advances-two-drug-development-programs-with-cdsco-regulatory-approvals 2025-09-25T13:14:49+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-analysis-reveals-new-safety-signals-for-sonidegib-in-basal-cell-carcinoma-treatment 2025-09-25T13:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-presents-breakthrough-cancer-data-at-esmo-2025-showcasing-unprecedented-survival-results 2025-09-25T13:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-qulipta-gains-public-reimbursement-in-quebec-for-migraine-prevention 2025-09-25T13:14:19+00:00 hourly 0.9 https://trial.medpath.com/news/levicept-s-levi-04-shows-dual-benefit-in-osteoarthritis-reduces-bone-marrow-lesions-while-alleviating-pain 2025-09-25T13:13:24+00:00 hourly 0.9 https://trial.medpath.com/news/pi-health-partners-with-gsk-to-accelerate-phase-2-oncology-trial-using-ai-powered-platform 2025-09-25T13:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-three-draft-guidances-to-accelerate-cell-and-gene-therapy-development-through-innovative-trial-designs 2025-09-25T13:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/marine-sponge-compounds-show-promise-as-novel-leishmaniasis-treatments 2025-09-25T09:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/sequana-medical-advances-us-commercialization-of-alfapump-system-with-cms-reimbursement-approval 2025-09-25T09:16:55+00:00 hourly 0.9 https://trial.medpath.com/news/penn-medicine-develops-novel-mrna-vaginal-gel-therapy-for-heavy-menstrual-bleeding 2025-09-25T09:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/huntington-s-disease-pipeline-shows-strong-growth-with-over-20-companies-developing-novel-therapies 2025-09-25T09:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/monash-university-researchers-develop-entelli-02-phage-cocktail-to-combat-antimicrobial-resistant-enterobacter-infections 2025-09-25T09:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/essa-pharma-amends-xenotherapeutics-agreement-reduces-shareholder-payout-to-0-12-per-share 2025-09-25T09:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/advocate-health-launches-nation-s-largest-clinical-trial-network-with-69-hospitals-and-six-million-patients 2025-09-25T09:13:43+00:00 hourly 0.9 https://trial.medpath.com/news/global-medical-research-funders-unite-to-strengthen-clinical-trial-standards-worldwide 2025-09-25T09:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-partners-with-evestia-clinical-for-phase-1b-trial-of-clr-125-radiopharmaceutical-in-triple-negative-breast-cancer 2025-09-25T07:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/rapid-car-t-cell-expansion-linked-to-delayed-neurotoxicity-risk-in-multiple-myeloma-patients-receiving-cilta-cel 2025-09-25T05:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/st-louis-children-s-hospital-begins-administering-fda-approved-gene-therapy-lyfgenia-for-sickle-cell-disease 2025-09-25T05:16:52+00:00 hourly 0.9 https://trial.medpath.com/news/manas-ai-secures-26-million-seed-extension-to-advance-ai-driven-drug-discovery-platform 2025-09-25T05:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/startnewera-phase-ii-trial-shows-promising-5-year-outcomes-for-stereotactic-radiotherapy-in-advanced-lung-cancer 2025-09-25T05:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/recce-pharmaceuticals-initiates-phase-3-trial-for-novel-diabetic-foot-infection-treatment-in-indonesia 2025-09-25T05:16:24+00:00 hourly 0.9 https://trial.medpath.com/news/hetlioz-demonstrates-significant-sleep-improvement-in-primary-insomnia-trial-published-in-plos-one 2025-09-25T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/seven-year-study-reveals-hidden-pre-clinical-stage-of-rheumatoid-arthritis 2025-09-25T01:28:47+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-and-ge-healthcare-partner-to-bring-psma-pet-imaging-agent-pylarify-to-japan-s-prostate-cancer-market 2025-09-25T01:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-opens-first-uk-mrna-manufacturing-facility-in-oxfordshire-strengthening-pandemic-preparedness 2025-09-25T01:23:16+00:00 hourly 0.9 https://trial.medpath.com/news/kashiv-biosciences-and-jamp-pharma-launch-neutropenia-biosimilars-in-canada 2025-09-25T01:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/faeth-therapeutics-reports-positive-phase-2-results-for-sapanisertib-in-ovarian-cancer-treatment 2025-09-25T01:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/duke-researchers-identify-stk17b-kinase-as-key-target-for-overcoming-multiple-myeloma-drug-resistance 2025-09-25T01:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/inhaled-heparin-reduces-covid-19-ventilation-risk-by-50-in-international-trial 2025-09-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dr-park-cdmo-partners-with-thermo-fisher-to-expand-viral-vector-manufacturing-capacity-in-south-korea 2025-09-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/camkk2-enzyme-knockout-in-immune-cells-prevents-diet-induced-obesity-and-diabetes-in-mice 2025-09-24T17:21:50+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-biosciences-zyn002-phase-3-trial-fails-to-meet-primary-endpoint-in-fragile-x-syndrome 2025-09-24T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/quantumzyme-secures-uspto-patent-for-green-enzymatic-ibuprofen-manufacturing-process 2025-09-24T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/replicate-bioscience-s-self-replicating-rna-rabies-vaccine-shows-superior-durability-in-phase-i-trial 2025-09-24T17:20:38+00:00 hourly 0.9 https://trial.medpath.com/news/aera-therapeutics-nominates-aera-109-as-first-development-candidate-for-in-vivo-car-t-therapy 2025-09-24T17:20:25+00:00 hourly 0.9 https://trial.medpath.com/news/immorta-bio-s-senovax-shows-strongest-senolytic-activity-in-preclinical-cte-model 2025-09-24T17:19:54+00:00 hourly 0.9 https://trial.medpath.com/news/aro-biotherapeutics-completes-enrollment-in-phase-1b-trial-of-novel-sirna-therapy-for-late-onset-pompe-disease 2025-09-24T17:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/sapu-nano-s-injectable-everolimus-formulation-sapu003-receives-approval-for-phase-1-breast-cancer-trial 2025-09-24T17:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/veracyte-presents-first-prospective-validation-data-for-hormone-therapy-biomarker-in-recurrent-prostate-cancer-at-astro-2025 2025-09-24T17:19:32+00:00 hourly 0.9 https://trial.medpath.com/news/fyr-bio-secures-8-million-to-advance-blood-based-biomarkers-for-brain-cancer-and-neurodegeneration 2025-09-24T17:18:37+00:00 hourly 0.9 https://trial.medpath.com/news/resvita-bio-receives-fda-clearance-to-advance-novel-bacterial-therapy-for-rare-skin-disease 2025-09-24T17:16:23+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-receives-tentative-fda-approval-for-generic-hiv-treatment-targeting-16-2-billion-market 2025-09-24T17:15:50+00:00 hourly 0.9 https://trial.medpath.com/news/ipca-laboratories-partners-with-biosimilar-sciences-for-us-manufacturing-of-cancer-and-autoimmune-biosimilars 2025-09-24T17:15:48+00:00 hourly 0.9 https://trial.medpath.com/news/hovione-partners-with-microinnova-to-advance-modular-flow-chemistry-manufacturing-technology 2025-09-24T17:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/cognision-and-somnomedics-partner-to-advance-sleep-biomarkers-in-cns-drug-development 2025-09-24T17:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/jaguar-health-seeks-orphan-drug-designation-for-crofelemer-in-breast-cancer-brain-metastasis-patients 2025-09-24T17:14:26+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-achieves-first-successful-treatment-of-huntington-s-disease-slowing-progression-by-75 2025-09-24T17:13:37+00:00 hourly 0.9 https://trial.medpath.com/news/scitech-development-raises-5-5-million-for-nanotechnology-cancer-drug-following-100-disease-control-rate-in-t-cell-lymphoma-trials 2025-09-24T17:13:32+00:00 hourly 0.9 https://trial.medpath.com/news/inato-partners-with-realtime-to-enhance-clinical-trial-site-selection-and-patient-enrollment 2025-09-24T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/rhode-island-hospital-launches-first-in-nation-trial-combining-focused-ultrasound-with-immunotherapy-for-brain-metastases 2025-09-24T17:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/cyclerion-therapeutics-pivots-to-neuropsychiatry-with-mit-licensed-treatment-resistant-depression-program 2025-09-24T14:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/uniqure-secures-175-million-loan-facility-to-support-amt-130-gene-therapy-launch-for-huntington-s-disease 2025-09-24T14:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/ocrelizumab-demonstrates-superior-multiple-sclerosis-relapse-control-in-large-real-world-registry-analysis 2025-09-24T14:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/northstar-medical-radioisotopes-partners-with-university-of-wisconsin-to-accelerate-radiopharmaceutical-development 2025-09-24T14:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/inoviq-s-car-nk-exosomes-demonstrate-61-5-tumor-reduction-in-triple-negative-breast-cancer-study 2025-09-24T14:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-enhertu-plus-pertuzumab-as-first-new-first-line-treatment-for-her2-positive-metastatic-breast-cancer-in-a-decade 2025-09-24T14:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/genelux-reports-q3-2025-results-as-olvi-vec-advances-toward-key-clinical-milestones 2025-09-24T14:20:59+00:00 hourly 0.9 https://trial.medpath.com/news/bispecific-antibody-tobemstomig-shows-promise-in-neoadjuvant-melanoma-trial-despite-discontinued-development 2025-09-24T14:20:11+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-phase-3-trial-of-intranasal-carbetocin-for-prader-willi-syndrome-fails-to-meet-primary-endpoint 2025-09-24T14:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-ventures-secures-625-million-to-accelerate-biotech-and-digital-health-investments 2025-09-24T14:18:41+00:00 hourly 0.9 https://trial.medpath.com/news/sensory-cloud-s-sc0023-shows-34-cough-reduction-in-phase-ii-refractory-chronic-cough-trial 2025-09-24T14:17:04+00:00 hourly 0.9 https://trial.medpath.com/news/gccl-and-frontage-laboratories-form-strategic-partnership-to-enhance-global-clinical-trial-capabilities 2025-09-24T14:15:31+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-launches-first-large-scale-u-s-trial-testing-ai-in-breast-cancer-screening 2025-09-24T14:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-oncoguide-oncoscreen-plus-cdx-system-for-breast-cancer-companion-diagnostics 2025-09-24T14:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/xeltis-achieves-breakthrough-results-in-eu-phase-3-trial-for-revolutionary-hemodialysis-vascular-access-device 2025-09-24T14:14:58+00:00 hourly 0.9 https://trial.medpath.com/news/igc-pharma-s-tgr-63-shows-dual-target-activity-against-alzheimer-s-pathology-in-preclinical-studies 2025-09-24T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/macumira-receives-first-health-canada-approval-for-non-invasive-dry-amd-treatment-device 2025-09-24T09:16:25+00:00 hourly 0.9 https://trial.medpath.com/news/synendos-therapeutics-advances-first-in-class-seri-compound-syt-510-to-phase-2-following-positive-phase-1-results 2025-09-24T09:14:27+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-intrepid-trial-confirms-long-term-benefits-of-subthalamic-deep-brain-stimulation-for-parkinson-s-disease 2025-09-24T06:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-researchers-present-breakthrough-177lutetium-psma-therapy-results-for-recurrent-prostate-cancer-at-astro-2025 2025-09-24T01:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/hemostemix-submits-fda-pre-ind-application-for-multi-indication-basket-trial-of-autologous-stem-cell-therapy-acp-01 2025-09-24T01:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-breaks-precedent-with-literature-based-approval-for-leucovorin-in-cerebral-folate-deficiency 2025-09-24T01:21:23+00:00 hourly 0.9 https://trial.medpath.com/news/zimbabwe-selected-for-global-rollout-of-lenacapavir-breakthrough-twice-yearly-hiv-prevention-drug 2025-09-24T01:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/rion-partners-with-lonza-to-scale-commercial-production-of-platelet-derived-exosome-therapeutics 2025-09-23T21:34:58+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-develop-nano-cubosome-eyedrops-to-replace-painful-eye-injections-for-retinal-diseases 2025-09-23T21:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/celecor-s-zalunfiban-meets-primary-endpoints-in-phase-iii-stemi-trial 2025-09-23T21:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/transpire-bio-achieves-fda-filing-acceptance-for-generic-breo-ellipta-positioning-for-market-exclusivity 2025-09-23T21:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-alberta-develops-ai-powered-microbiome-test-for-personalized-ibd-treatment 2025-09-23T21:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/celecor-s-disaggpro-shows-positive-results-in-phase-3-trial-for-pre-hospital-stemi-treatment 2025-09-23T21:26:23+00:00 hourly 0.9 https://trial.medpath.com/news/ventoux-biosciences-secures-u-s-patent-for-novel-dupuytren-s-disease-treatment-approach 2025-09-23T21:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/expert-commentary-questions-hsk21542-efficacy-claims-for-chronic-kidney-disease-associated-pruritus 2025-09-23T21:24:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-finalizes-guidance-on-alternative-inspection-tools-for-drug-manufacturing-facilities 2025-09-23T21:23:58+00:00 hourly 0.9 https://trial.medpath.com/news/duke-engineers-develop-ai-powered-platform-to-optimize-nanoparticle-drug-delivery 2025-09-23T21:23:55+00:00 hourly 0.9 https://trial.medpath.com/news/medic-life-sciences-acquires-clinical-stage-oncology-program-using-sls-biomarker-platform-for-precision-medicine 2025-09-23T21:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/tgf-b-inhibitor-pipeline-expands-with-25-companies-developing-novel-therapies-for-cancer-and-fibrosis 2025-09-23T21:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/ncardia-launches-first-commercial-ipsc-derived-non-human-primate-cardiomyocytes-for-cardiac-safety-testing 2025-09-23T21:22:18+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-pharmaceuticals-receives-fda-approval-for-generic-bimatoprost-eye-drops-to-treat-glaucoma 2025-09-23T21:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/anova-launches-global-clinical-registry-to-accelerate-drug-development-and-patient-access 2025-09-23T21:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-upholds-generic-challenge-to-bayer-s-xarelto-patent-protection 2025-09-23T17:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-lipid-nanoparticle-vaccine-shows-promise-against-severe-allergic-reactions-in-preclinical-study 2025-09-23T17:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-s-iberdomide-combination-achieves-primary-endpoint-in-phase-3-multiple-myeloma-trial 2025-09-23T17:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-rules-clinically-proven-effective-claims-cannot-rescue-anticipated-drug-methods-from-prior-art 2025-09-23T17:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/opdivo-subcutaneous-formulation-receives-positive-reimbursement-recommendation-in-quebec 2025-09-23T17:30:46+00:00 hourly 0.9 https://trial.medpath.com/news/onconetix-subsidiary-proteomedix-licenses-manufacturing-ip-to-immunovia-for-pancreasure-pancreatic-cancer-test 2025-09-23T17:30:03+00:00 hourly 0.9 https://trial.medpath.com/news/kinea-bio-secures-1-1m-investment-and-aav-slb101-license-to-advance-dysferlinopathy-gene-therapy 2025-09-23T17:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/exmoor-pharma-and-siam-bioscience-partner-to-establish-southeast-asia-s-leading-cell-and-gene-therapy-manufacturing-hub 2025-09-23T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-scholar-rock-s-apitegromab-due-to-manufacturing-issues 2025-09-23T17:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/prellis-biologics-partners-with-eli-lilly-to-accelerate-antibody-discovery-using-novel-biological-ai-platform 2025-09-23T17:26:11+00:00 hourly 0.9 https://trial.medpath.com/news/triveni-bio-initiates-phase-2-trial-of-novel-anti-klk5-7-antibody-triv-509-for-atopic-dermatitis 2025-09-23T17:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/heartflow-receives-fda-clearance-for-next-generation-ai-plaque-analysis-platform-with-enhanced-detection-capabilities 2025-09-23T17:24:36+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-and-sophia-genetics-partner-to-develop-global-liquid-biopsy-companion-diagnostic-platform 2025-09-23T17:24:01+00:00 hourly 0.9 https://trial.medpath.com/news/santhera-secures-chf-20-million-growth-funding-to-accelerate-global-agamree-rollout-for-duchenne-muscular-dystrophy 2025-09-23T17:23:52+00:00 hourly 0.9 https://trial.medpath.com/news/digital-outreach-study-reveals-major-diagnostic-gap-in-dysmenorrhea-affecting-thousands-of-european-women 2025-09-23T17:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/allergan-aesthetics-expands-skinvive-injectable-treatment-to-35-new-global-markets 2025-09-23T17:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/cms-secures-exclusive-rights-to-two-breakthrough-antibody-therapies-for-tetanus-and-rabies-prevention 2025-09-23T13:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/aptahem-secures-chinese-patent-protection-for-rna-based-anti-inflammatory-therapy-through-2038 2025-09-23T13:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/icr-and-enamine-launch-fragment-based-drug-discovery-collaboration-to-accelerate-cancer-drug-development 2025-09-23T13:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/daltontx-emerges-from-stealth-with-ps4m-seed-funding-to-transform-drug-discovery-with-adaptive-ai-platform 2025-09-23T13:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/softox-solutions-advances-cystic-fibrosis-treatment-with-phase-2a-trial-application-and-stability-breakthrough 2025-09-23T13:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/virtuoso-surgical-robotic-system-receives-fda-breakthrough-device-designation-for-bladder-cancer-surgery 2025-09-23T13:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/healx-partners-with-vuja-de-sciences-to-advance-ai-driven-therapy-for-metastatic-osteosarcoma-recurrence 2025-09-23T09:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-therapeutics-appoints-cmo-and-cto-to-advance-hmbd-002-cancer-immunotherapy-toward-phase-ii-trial 2025-09-23T09:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/merck-and-siemens-expand-partnership-to-accelerate-ai-driven-drug-discovery-and-manufacturing 2025-09-23T09:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-advances-denosumab-biosimilar-following-phase-3-success-eyes-7-billion-market-entry 2025-09-23T09:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/altria-partners-with-kt-g-to-expand-global-nicotine-pouch-and-wellness-product-portfolio 2025-09-23T08:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-unveil-crispr-gpt-ai-powered-system-accelerates-gene-editing-experiments 2025-09-23T05:17:20+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-s-next-generation-ret-inhibitor-a400-ep0031-receives-nda-acceptance-in-china-for-nsclc-treatment 2025-09-23T05:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/algorae-pharmaceuticals-expands-commercial-portfolio-through-strategic-partnerships-in-australia-and-new-zealand 2025-09-23T05:14:49+00:00 hourly 0.9 https://trial.medpath.com/news/catalym-initiates-phase-2b-trial-of-visugromab-in-first-line-metastatic-nsclc 2025-09-23T01:18:10+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-links-acetaminophen-to-autism-risk-triggering-sharp-decline-in-kenvue-stock 2025-09-23T01:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/arrivent-biopharma-appoints-brent-rice-as-chief-commercial-officer-to-lead-firmonertinib-commercialization 2025-09-23T01:17:41+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-and-sirius-therapeutics-dose-first-patient-in-phase-2-trial-of-srsd107-for-venous-thromboembolism-prevention 2025-09-23T01:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/eupraxia-pharmaceuticals-announces-public-offering-to-advance-extended-release-drug-pipeline 2025-09-23T01:14:23+00:00 hourly 0.9 https://trial.medpath.com/news/salt-ai-secures-10-million-to-advance-contextual-ai-platform-for-life-sciences 2025-09-23T01:14:02+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-to-submit-label-update-for-leucovorin-following-fda-request-for-cerebral-folate-deficiency-treatment 2025-09-23T01:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/cps-technologies-secures-1-15m-army-contract-for-advanced-tungsten-warhead-development 2025-09-23T01:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-receives-ema-approval-for-generic-rivaroxaban-orodispersible-films 2025-09-23T01:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/kt-g-signs-comprehensive-mou-with-altria-for-nicotine-pouch-and-health-functional-foods-collaboration 2025-09-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tegmine-therapeutics-partners-with-boehringer-ingelheim-to-develop-next-generation-adcs-using-novel-2-factor-antibody-system 2025-09-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/myocardial-infarction-pipeline-shows-promise-with-40-therapies-in-development-across-multiple-clinical-phases 2025-09-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cellares-strengthens-leadership-team-with-key-commercial-and-advisory-appointments-to-drive-cell-therapy-manufacturing-expansion 2025-09-22T21:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/mindwalk-unveils-ai-designed-dual-pathway-glp-1-regimen-targeting-60b-longevity-market 2025-09-22T21:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-cytocell-kmt2a-companion-diagnostic-for-revumenib-in-acute-leukemia 2025-09-22T21:18:42+00:00 hourly 0.9 https://trial.medpath.com/news/patient-square-capital-acquires-healthcare-technology-firm-premier-for-2-6-billion 2025-09-22T21:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/enzene-launches-commercial-supply-of-pertuzumab-biosimilar-using-continuous-manufacturing-technology 2025-09-22T21:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-s-melbourne-mrna-facility-could-save-australia-4-8-billion-in-future-pandemic-costs 2025-09-22T21:15:48+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-salmonella-bacteria-show-promise-in-colorectal-cancer-treatment-through-immune-system-activation 2025-09-22T21:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/median-technologies-secures-eur61-4m-financing-extends-cash-runway-through-2026-as-ai-cancer-diagnostic-tool-awaits-fda-clearance 2025-09-22T21:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-may-reshape-generic-drug-labeling-practices-in-landmark-patent-infringement-case 2025-09-22T21:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/alcon-staar-surgical-merger-advances-as-hart-scott-rodino-waiting-period-expires 2025-09-22T18:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/tubulis-reports-promising-phase-i-iia-data-for-tub-040-adc-in-platinum-resistant-ovarian-cancer 2025-09-22T17:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/cerevance-reports-positive-phase-2-results-for-novel-non-dopaminergic-parkinson-s-treatment-solengepras 2025-09-22T17:24:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-subcutaneous-pd-1-inhibitor-as-msd-launches-keytruda-qlex 2025-09-22T17:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-acquires-obesity-drug-developer-metsera-in-strategic-move-to-enter-weight-management-market 2025-09-22T17:23:56+00:00 hourly 0.9 https://trial.medpath.com/news/lynk-labs-challenges-federal-circuit-s-patent-prior-art-interpretation-in-supreme-court-petition 2025-09-22T17:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/aim-immunotech-s-ampligen-shows-synergistic-effect-with-interferon-alpha-in-overcoming-pd-1-resistance-in-cold-tumors 2025-09-22T17:22:18+00:00 hourly 0.9 https://trial.medpath.com/news/cdi-therapeutics-market-shows-promise-with-48-molecule-pipeline-and-over-2-million-annual-cases 2025-09-22T17:21:58+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-promotes-leucovorin-as-potential-autism-treatment-despite-limited-clinical-evidence 2025-09-22T17:21:41+00:00 hourly 0.9 https://trial.medpath.com/news/netramark-partners-with-academic-medical-center-to-apply-ai-platform-for-glioblastoma-trial-optimization 2025-09-22T17:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/avenzo-therapeutics-secures-60-million-series-b-to-advance-next-generation-oncology-pipeline 2025-09-22T17:17:09+00:00 hourly 0.9 https://trial.medpath.com/news/angelini-pharma-secures-exclusive-option-for-sovargen-s-novel-brain-health-asset-svg105 2025-09-22T17:17:07+00:00 hourly 0.9 https://trial.medpath.com/news/zealand-pharma-explores-direct-to-consumer-sales-for-novel-amylin-based-obesity-drug-petrelintide 2025-09-22T17:16:22+00:00 hourly 0.9 https://trial.medpath.com/news/alkem-laboratories-launches-affordable-pertuzumab-biosimilar-for-her2-positive-breast-cancer-in-india 2025-09-22T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-partners-with-george-washington-university-for-phase-ii-neoadjuvant-breast-cancer-trial 2025-09-22T17:14:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-mavrix-bio-s-mvx-220-gene-therapy-for-angelman-syndrome 2025-09-22T17:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-publishes-new-variations-guidelines-to-streamline-drug-lifecycle-management 2025-09-22T17:12:32+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-receives-fda-510-k-clearance-for-rna-based-cancer-diagnostic-device 2025-09-22T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/techsomed-expands-ai-powered-biotraceio360-platform-to-kidney-ablation-following-fda-510-k-clearance 2025-09-22T17:12:24+00:00 hourly 0.9 https://trial.medpath.com/news/usc-scientists-create-most-advanced-lab-grown-kidney-structures-with-real-function-for-disease-modeling 2025-09-22T17:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-and-bristol-myers-squibb-report-promising-phase-2-results-for-pumitamig-in-triple-negative-breast-cancer 2025-09-22T17:11:48+00:00 hourly 0.9 https://trial.medpath.com/news/sharp-services-announces-100-million-global-investment-to-expand-injectable-drug-manufacturing-capacity 2025-09-22T13:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/nuclide-therapeutics-secures-ps5m-to-advance-aldh1a1-targeted-radiotheranostics-for-therapy-resistant-cancers 2025-09-22T13:15:12+00:00 hourly 0.9 https://trial.medpath.com/news/hetero-healthcare-and-enzene-launch-perzea-india-s-most-affordable-pertuzumab-biosimilar-for-her2-positive-breast-cancer 2025-09-22T13:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/european-medicines-agency-recommends-approval-of-alvotech-s-gobivaz-biosimilar-to-johnson-johnson-s-simponi 2025-09-22T13:13:53+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-secures-multiple-fda-approvals-boosting-pharmaceutical-portfolio-and-market-outlook 2025-09-22T13:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/tolvaptan-shows-promise-as-universal-pharmacological-chaperone-for-rare-disease-treatment 2025-09-22T13:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/n4-pharma-s-nuvec-delivery-system-achieves-targeted-rna-delivery-to-lung-cancer-cells 2025-09-22T13:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/ensoma-secures-53-million-to-advance-first-in-class-gene-therapy-for-x-linked-chronic-granulomatous-disease 2025-09-22T13:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/debra-research-and-nonsense-therapeutics-form-readon-therapeutics-to-advance-epidermolysis-bullosa-treatments 2025-09-22T13:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/phase-scientific-launches-world-s-largest-urine-based-hpv-screening-study-with-17000-participants 2025-09-22T13:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-plans-2026-uk-launch-of-breakthrough-schizophrenia-drug-cobenfy-at-22500-annual-price 2025-09-22T13:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/c4x-discovery-selects-once-daily-oral-a4b7-inhibitor-candidate-for-inflammatory-bowel-disease-treatment 2025-09-22T09:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/gc-green-cross-submits-phase-1-clinical-trial-application-for-covid-19-mrna-vaccine-in-south-korea 2025-09-22T09:18:59+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-pursues-7-3-billion-acquisition-of-metsera-to-enter-rapidly-expanding-anti-obesity-drug-market 2025-09-22T09:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-tezspire-receives-eu-regulatory-recommendation-for-chronic-rhinosinusitis-with-nasal-polyps 2025-09-22T09:16:28+00:00 hourly 0.9 https://trial.medpath.com/news/myricx-bio-appoints-new-ceo-as-company-advances-novel-adc-platform-toward-clinical-trials 2025-09-22T09:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/idorsia-s-quviviq-launches-in-china-through-simcere-partnership-expanding-global-reach-of-novel-insomnia-treatment 2025-09-22T09:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-s-ipn10200-shows-superior-long-term-efficacy-in-phase-ii-glabellar-lines-trial 2025-09-22T09:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-giredestrant-combination-meets-phase-iii-endpoints-in-advanced-breast-cancer 2025-09-22T09:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/proteomics-international-achieves-iso-15189-certification-accelerates-commercial-launch-of-precision-diagnostic-tests 2025-09-22T09:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-in-human-trial-for-lbl-047-novel-bispecific-protein-targeting-autoimmune-diseases 2025-09-22T09:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/crossject-receives-additional-11-3m-barda-funding-for-zepizure-needle-free-epilepsy-treatment 2025-09-22T09:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-ianalumab-combination-shows-45-improvement-in-itp-disease-control-in-phase-iii-trial 2025-09-22T07:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/yangtze-river-pharmaceutical-unveils-phase-iii-results-for-novel-insomnia-drug-fazamorexant-at-world-sleep-congress 2025-09-22T05:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/gemvax-seeks-fda-breakthrough-therapy-designation-for-gv1001-in-progressive-supranuclear-palsy 2025-09-22T05:17:44+00:00 hourly 0.9 https://trial.medpath.com/news/ceretas-secures-2-4-million-government-grant-to-advance-non-invasive-ultrasound-therapy-for-alzheimer-s-disease 2025-09-22T05:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/ltr-pharma-increases-stake-in-levomega-to-43-with-1m-investment-for-sustainable-omega-3-development 2025-09-22T01:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/positive-trial-shows-tildrakizumab-delivers-comprehensive-quality-of-life-benefits-in-psoriatic-disease 2025-09-21T21:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-secures-fda-approval-for-altaviva-tibial-neuromodulation-device-becomes-sole-provider-of-complete-bladder-control-portfolio 2025-09-21T21:11:28+00:00 hourly 0.9 https://trial.medpath.com/news/magnesium-supplements-show-promise-for-colorectal-cancer-prevention-through-gut-microbiome-modulation 2025-09-21T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-helios-trial-shows-promise-for-otx-tki-in-diabetic-retinopathy-treatment 2025-09-21T17:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-infiltrating-lymphocytes-and-macrophages-drive-cancer-immunoediting-through-three-critical-phases 2025-09-21T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/henagliflozin-shows-promise-as-anti-aging-therapy-in-type-2-diabetes-patients 2025-09-21T13:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/our-lady-of-the-lake-cancer-institute-launches-louisiana-s-first-allogeneic-car-t-cell-therapy-clinical-trial 2025-09-21T13:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/iranian-researchers-develop-ai-powered-personalized-mrna-vaccine-for-lung-cancer 2025-09-21T13:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/avidity-biosciences-advances-rna-therapeutics-with-clinical-trials-for-rare-diseases 2025-09-21T12:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-show-austedo-xr-delivers-high-patient-satisfaction-and-movement-improvement-in-tardive-dyskinesia 2025-09-21T09:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/teva-s-olanzapine-lai-shows-no-pdss-events-in-56-week-phase-3-trial-paving-way-for-first-long-acting-olanzapine-treatment 2025-09-21T05:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/pegasus-laboratories-expands-florida-manufacturing-facility-to-meet-growing-veterinary-drug-demand 2025-09-21T01:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/mmrf-presents-breakthrough-multiple-myeloma-research-at-international-conference-revealing-immune-system-changes-during-treatment 2025-09-21T01:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/genfit-discontinues-vs-01-development-in-liver-failure-following-safety-concerns-refocuses-on-rare-disease 2025-09-20T21:13:30+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-receives-four-fda-observations-at-pune-biotech-facility-following-pre-approval-inspection 2025-09-20T21:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/faers-analysis-reveals-lower-infection-risk-with-ide-cel-compared-to-other-bcma-targeted-therapies-in-multiple-myeloma 2025-09-20T21:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/elutia-s-biologic-envelope-shows-43-reduction-in-cied-reoperation-difficulty-in-heal-study 2025-09-20T21:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/savara-receives-fda-alignment-on-molbreevi-bla-resubmission-stock-surges-15-76-following-strategic-financing 2025-09-20T17:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/faraday-future-invests-41-million-in-qualigen-therapeutics-for-strategic-pivot-to-cryptocurrency-and-web3-business 2025-09-20T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/large-australian-trial-finds-pneumococcal-vaccine-ineffective-for-cardiovascular-protection 2025-09-20T10:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/two-major-nih-grants-totaling-7-3-million-fund-groundbreaking-adhd-medication-research 2025-09-20T09:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-advisory-committee-delays-vote-on-proposed-changes-to-newborn-hepatitis-b-vaccination-schedule 2025-09-20T09:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-reports-positive-phase-3-results-for-darzalex-faspro-combination-in-newly-diagnosed-multiple-myeloma 2025-09-20T05:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-injectable-keytruda-marking-new-era-in-cancer-treatment-convenience 2025-09-20T01:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-biomed-launches-a-perfusctm-3d-cell-culture-platform-for-enhanced-drug-discovery-and-precision-medicine 2025-09-20T01:12:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-hdt-bio-s-first-in-class-hdt-321-for-crimean-congo-hemorrhagic-fever-prevention 2025-09-19T21:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/six-year-upadacitinib-safety-data-shows-comparable-cardiovascular-risk-in-atopic-dermatitis-patients 2025-09-19T21:13:56+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-challenges-regeneron-s-high-dose-aflibercept-patent-in-post-grant-review 2025-09-19T21:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-amgen-s-uplizna-for-rare-autoimmune-disease-igg4-rd 2025-09-19T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-subcutaneous-pembrolizumab-formulation-for-solid-tumors-reducing-treatment-time-by-nearly-50 2025-09-19T21:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/r-pharm-presents-long-term-olokizumab-data-showing-sustained-improvement-in-rheumatoid-arthritis-patients 2025-09-19T17:20:38+00:00 hourly 0.9 https://trial.medpath.com/news/curateq-biologics-completes-successful-phase-3-trial-for-denosumab-biosimilar-in-postmenopausal-osteoporosis 2025-09-19T17:20:06+00:00 hourly 0.9 https://trial.medpath.com/news/elicera-therapeutics-faces-u-s-patent-setback-for-itank-car-t-enhancement-platform 2025-09-19T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-receives-japanese-approval-for-nexletol-as-novel-non-statin-cholesterol-treatment 2025-09-19T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/bluebird-bio-rebrands-as-genetix-biotherapeutics-following-private-buyout-refocuses-on-gene-therapy-access 2025-09-19T17:18:37+00:00 hourly 0.9 https://trial.medpath.com/news/eckert-ziegler-receives-japanese-approval-for-galliapharm-r-generator-expanding-gallium-68-diagnostics-for-prostate-cancer 2025-09-19T17:18:20+00:00 hourly 0.9 https://trial.medpath.com/news/tecvayli-and-darzalex-faspro-combination-achieves-100-mrd-negativity-in-newly-diagnosed-multiple-myeloma-patients 2025-09-19T17:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/precision-biologics-reports-promising-efficacy-data-for-novel-ovarian-cancer-adc-pb-vcmmae-5 2025-09-19T17:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/lexaria-s-dehydratech-technology-enhances-semaglutide-brain-delivery-in-preclinical-study 2025-09-19T17:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/indoco-remedies-achieves-zero-fda-observations-at-mumbai-api-manufacturing-facility 2025-09-19T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-secures-japanese-approval-for-three-biosimilars-including-first-global-golimumab-biosimilar 2025-09-19T17:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/kindeva-opens-150000-sq-ft-uk-facility-to-develop-environmentally-friendly-inhaler-propellants 2025-09-19T17:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-recommend-approval-for-novo-nordisk-s-weekly-diabetes-combination-therapy-kyinsu 2025-09-19T17:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-medtronic-s-altaviva-implantable-device-for-urge-urinary-incontinence 2025-09-19T17:11:50+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-s-bylvay-receives-japanese-approval-for-rare-liver-disease-pfic-offering-first-non-surgical-treatment-option 2025-09-19T17:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-clinical-trials-demonstrate-efficacy-of-il-13-and-il-4-il-13-inhibitors-in-patients-with-darker-skin-tones 2025-09-19T17:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/datavant-and-indegene-partner-to-accelerate-clinical-trial-recruitment-for-rare-diseases 2025-09-19T17:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-early-alert-for-abbott-s-tactiflex-ablation-catheter-following-tip-detachment-reports 2025-09-19T13:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/genflow-biosciences-files-patent-examination-request-in-china-for-sirt6-based-nash-therapy 2025-09-19T13:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/ema-approves-first-treatment-for-non-cystic-fibrosis-bronchiectasis-as-16-new-medicines-receive-marketing-authorization 2025-09-19T13:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/ql-biopharm-s-zovaglutide-achieves-13-8-weight-loss-with-monthly-dosing-in-phase-2-trial 2025-09-19T13:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-receives-japanese-approval-for-tecentriq-in-rare-lymphoma-marking-first-checkpoint-inhibitor-for-enkl 2025-09-19T13:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/vitamin-b3-derivative-shows-54-reduction-in-skin-cancer-risk-in-large-veterans-study 2025-09-19T09:15:02+00:00 hourly 0.9 https://trial.medpath.com/news/iaso-biotherapeutics-reports-sustained-36-month-efficacy-data-for-fucaso-car-t-therapy-in-multiple-myeloma 2025-09-19T09:14:41+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-liver-cancer-pipeline-shows-robust-growth-with-50-companies-developing-novel-therapies 2025-09-19T09:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-targets-7-billion-global-biosimilar-market-with-fda-approved-denosumab-products 2025-09-19T09:11:29+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-advisory-panel-votes-to-limit-combined-mmrv-vaccine-use-in-young-children-due-to-seizure-risk 2025-09-19T09:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/kane-biotech-submits-fda-510-k-application-for-third-revyve-wound-care-product 2025-09-19T05:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/sight-sciences-omni-system-gains-unitedhealthcare-coverage-as-meta-analysis-confirms-long-term-efficacy-in-glaucoma-treatment 2025-09-19T05:14:31+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-advisory-committee-narrows-mmrv-vaccine-recommendations-signals-potential-changes-to-covid-19-and-hepatitis-b-guidelines 2025-09-19T05:14:28+00:00 hourly 0.9 https://trial.medpath.com/news/exsight-ventures-backs-revopsis-therapeutics-novel-tri-specific-antibody-platform-for-retinal-diseases 2025-09-19T05:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/genedx-strengthens-leadership-team-with-key-appointments-to-advance-ai-powered-precision-medicine 2025-09-19T05:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/aurora-spine-launches-world-s-first-bone-density-matched-spinal-implant-for-lumbar-fusion 2025-09-19T05:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-antithymocyte-globulin-shows-promise-for-type-1-diabetes-treatment-in-youth 2025-09-19T01:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/roche-acquires-89bio-to-expand-cardiometabolic-pipeline-beyond-glp-1-competition 2025-09-19T01:14:07+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-settles-patent-dispute-with-alnylam-over-covid-19-vaccine-technology 2025-09-19T01:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/cevostamab-consolidation-after-car-t-therapy-shows-93-mrd-negative-response-rate-in-heavily-pretreated-multiple-myeloma 2025-09-19T01:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-secures-italian-reimbursement-for-crispr-gene-therapy-casgevy-expanding-european-access-for-blood-disorders 2025-09-19T01:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-stocks-surge-after-hours-as-investors-anticipate-key-clinical-trial-results 2025-09-19T01:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/weill-cornell-medicine-receives-20-8-million-nih-grant-to-develop-childhood-hiv-vaccine 2025-09-19T01:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/gerd-pipeline-shows-promise-with-novel-p-cab-therapies-advancing-through-late-stage-trials 2025-09-19T01:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/mink-therapeutics-appoints-dr-terese-hammond-to-lead-inkt-cell-therapy-pipeline-toward-pivotal-trials 2025-09-18T21:19:21+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-launches-first-omalizumab-biosimilar-omlyclo-in-europe-starting-with-norway 2025-09-18T21:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/nt-301-nasal-spray-shows-promising-phase-1-results-for-parkinson-s-disease-off-episodes 2025-09-18T21:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/trevi-therapeutics-presents-nalbuphine-er-data-at-major-respiratory-conferences-following-positive-phase-2-trials 2025-09-18T21:14:13+00:00 hourly 0.9 https://trial.medpath.com/news/vectory-therapeutics-secures-1-2b-deal-for-shape-s-brain-penetrant-aav-capsid-technology 2025-09-18T21:13:28+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-demonstrates-promise-as-one-time-treatment-for-alpha-thalassemia 2025-09-18T21:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/med-safety-mobile-app-increases-adverse-drug-reaction-reporting-by-73-in-uganda-trial 2025-09-18T21:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/formation-bio-strengthens-leadership-team-with-former-pfizer-and-benevolentai-executives-to-advance-ai-driven-drug-development 2025-09-18T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/kelyniam-global-receives-first-fda-clearance-for-bcp-peek-cranial-implants-in-eight-years 2025-09-18T21:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-hydrogen-peroxide-use-in-food-production-opening-new-market-for-tomi-s-steramist-technology 2025-09-18T21:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/stryker-opens-140000-square-foot-r-d-innovation-center-in-bengaluru-to-advance-medical-technology 2025-09-18T20:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/early-hormone-therapy-reduces-alzheimer-s-risk-by-32-in-postmenopausal-women-new-meta-analysis-shows 2025-09-18T19:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/iveena-secures-2-million-nih-grant-to-advance-first-in-class-pediatric-myopia-eye-drop 2025-09-18T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-demonstrates-significant-metabolic-benefits-in-schizophrenia-patients-on-antipsychotic-therapy 2025-09-18T17:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/merck-invests-eur150-million-in-advanced-filtration-manufacturing-facility-in-ireland 2025-09-18T17:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-drug-delivery-technologies-drive-biotech-innovation-as-nanomedicine-market-approaches-430-billion 2025-09-18T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/geneos-therapeutics-reports-five-year-recurrence-free-survival-in-aggressive-brain-and-liver-cancer-patients-with-personalized-immunotherapy 2025-09-18T17:19:23+00:00 hourly 0.9 https://trial.medpath.com/news/cullgen-completes-phase-1-enrollment-for-novel-non-opioid-pain-therapy-cg001419 2025-09-18T17:18:38+00:00 hourly 0.9 https://trial.medpath.com/news/nkgen-biotech-to-present-troculeucel-clinical-data-for-alzheimer-s-disease-at-major-international-conferences 2025-09-18T17:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/atai-life-sciences-secures-11-4-million-nih-grant-for-non-hallucinogenic-opioid-use-disorder-treatment 2025-09-18T17:16:28+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-plans-q4-ind-filing-for-coronary-tissue-engineered-vessel-following-promising-primate-study 2025-09-18T17:15:32+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-acquires-alcyone-therapeutics-for-85m-to-advance-implantable-drug-delivery-system-for-neurological-therapies 2025-09-18T17:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/argenx-expands-partnership-with-fujifilm-biotechnologies-to-manufacture-efgartigimod-in-the-u-s 2025-09-18T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/alk-partners-with-gensci-to-overcome-chinese-regulatory-challenges-and-expand-into-immunotherapy 2025-09-18T17:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-pharmaceuticals-joins-alliance-for-genomic-discovery-to-accelerate-rnai-drug-development 2025-09-18T17:12:14+00:00 hourly 0.9 https://trial.medpath.com/news/organox-receives-fda-approval-for-air-transport-of-liver-perfusion-device-expanding-transplant-access-nationwide 2025-09-18T17:12:09+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-introduces-fast-track-drug-approval-system-to-reduce-review-time-by-33 2025-09-18T17:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/marengo-therapeutics-advances-phase-2-expansion-of-invikafusp-alfa-trodelvy-combination-for-metastatic-breast-cancer 2025-09-18T17:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-three-novel-hae-therapies-in-2025-ending-four-year-regulatory-drought 2025-09-18T17:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/brainlab-receives-fda-clearance-for-spine-mixed-reality-navigation-system 2025-09-18T17:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-drugmaker-jiangsu-hengrui-becomes-world-s-top-clinical-trial-sponsor-as-china-transforms-global-r-d-landscape 2025-09-18T17:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/closed-loop-medicine-launches-first-personalized-glp-1-dosing-platform-to-combat-high-discontinuation-rates 2025-09-18T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/mavenclad-shows-sustained-long-term-benefits-in-multiple-sclerosis-with-four-year-data-at-ectrims-2025 2025-09-18T13:13:58+00:00 hourly 0.9 https://trial.medpath.com/news/ovation-science-and-skinvisible-expand-thc-v-partnership-for-obesity-treatment-with-novel-transdermal-delivery-technology 2025-09-18T13:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/immuto-scientific-secures-8m-funding-and-daiichi-sankyo-partnership-to-advance-ai-driven-cancer-target-discovery 2025-09-18T13:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-updated-airsupra-label-showing-46-reduction-in-asthma-attacks-for-mild-asthma-patients 2025-09-18T13:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/biocardia-s-cardiamp-cell-therapy-shows-82-reduction-in-angina-episodes-in-chronic-myocardial-ischemia-trial 2025-09-18T13:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/roche-acquires-89bio-for-3-5-billion-to-strengthen-mash-treatment-pipeline 2025-09-18T13:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/greenwich-lifesciences-expands-flamingo-01-breast-cancer-trial-to-ireland-adding-to-global-network-of-150-sites 2025-09-18T13:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/cphi-frankfurt-2025-reveals-pharma-awards-finalists-highlighting-industry-innovation-and-sustainability 2025-09-18T10:51:13+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-s-brain-mechanism-revealed-after-60-years-new-pathway-could-transform-diabetes-treatment 2025-09-18T09:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/st-jude-researchers-develop-novel-combination-therapy-to-overcome-neuroblastoma-treatment-resistance 2025-09-18T09:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-s-galvokimig-shows-promise-in-phase-1-2a-trial-for-moderate-to-severe-atopic-dermatitis 2025-09-18T09:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/portuguese-startup-mondego-bio-secures-series-a-funding-to-develop-novel-ptpn2-inhibitors-for-cancer-immunotherapy 2025-09-18T09:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-test-predicts-semaglutide-response-in-post-bariatric-surgery-patients 2025-09-18T09:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/corestemchemon-s-neuronata-r-shows-significant-benefits-in-als-slow-progressors-in-phase-3-trial 2025-09-18T09:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/cocoa-extract-supplements-reduce-key-inflammatory-marker-in-large-clinical-trial 2025-09-18T05:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/stryker-and-siemens-healthineers-partner-to-develop-robotic-neurovascular-system-for-stroke-and-aneurysm-treatment 2025-09-18T05:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-s-zevor-cel-shows-exceptional-5-year-survival-data-in-relapsed-multiple-myeloma-patients 2025-09-18T05:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reversal-threatens-access-to-promising-duchenne-muscular-dystrophy-cell-therapy 2025-09-18T05:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/nanobiotix-s-jnj-1900-shows-promising-results-in-anti-pd-1-resistant-melanoma-patients 2025-09-18T01:18:14+00:00 hourly 0.9 https://trial.medpath.com/news/magicrna-s-in-vivo-car-t-therapy-hn2301-shows-promise-in-first-in-human-lupus-trial 2025-09-18T01:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/arsenal-biosciences-cuts-50-of-workforce-despite-325m-series-c-funding-round 2025-09-18T01:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-advisory-panel-delays-controversial-vote-on-newborn-hepatitis-b-vaccine-timing 2025-09-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-lamotrigine-oral-suspension-for-epilepsy-and-bipolar-disorder-treatment 2025-09-17T23:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/chronic-lower-back-pain-pipeline-shows-mixed-results-as-multiple-phase-iii-trials-report-outcomes 2025-09-17T21:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/crown-bioscience-opens-advanced-oncology-model-development-center-in-north-carolina 2025-09-17T21:16:11+00:00 hourly 0.9 https://trial.medpath.com/news/swiss-researchers-develop-dual-action-fusion-protein-for-enhanced-cancer-immunotherapy 2025-09-17T21:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/elranatamab-consolidation-therapy-shows-promise-in-deepening-response-after-car-t-treatment-in-multiple-myeloma 2025-09-17T21:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/eribulin-pyrotinib-combination-shows-promise-in-trastuzumab-resistant-her2-breast-cancer 2025-09-17T21:14:52+00:00 hourly 0.9 https://trial.medpath.com/news/wheeler-bio-partners-with-mindimmune-to-advance-first-in-class-alzheimer-s-therapy-miti-101 2025-09-17T21:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/oruka-therapeutics-orka-001-shows-100-day-half-life-in-phase-1-trial-potentially-enabling-annual-dosing-for-psoriasis 2025-09-17T21:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/changchun-high-tech-secures-eur177-7-million-deal-for-alk-s-house-dust-mite-allergy-immunotherapies-in-china 2025-09-17T21:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/bio-protocol-raises-6-9m-to-launch-ai-native-decentralized-science-platform-for-drug-discovery 2025-09-17T21:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-receives-fda-breakthrough-therapy-designation-for-r-dxd-in-ovarian-cancer 2025-09-17T21:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/arthex-biotech-secures-87m-series-b-to-advance-novel-rna-therapy-for-myotonic-dystrophy-type-1 2025-09-17T21:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/rgenta-therapeutics-receives-fda-orphan-drug-designation-for-rgt-61159-in-adenoid-cystic-carcinoma-treatment 2025-09-17T17:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/nurix-and-gilead-s-irak4-degrader-gs-6791-shows-promise-for-inflammatory-skin-diseases-in-preclinical-studies 2025-09-17T17:22:13+00:00 hourly 0.9 https://trial.medpath.com/news/character-biosciences-secures-110m-series-b-extension-expands-leadership-to-advance-amd-therapeutics 2025-09-17T17:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-publishes-breakthrough-research-on-microbial-bioproduction-of-neuropsychiatric-compounds 2025-09-17T17:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/tatum-bioscience-s-nanofilament-immunotherapy-tat003-demonstrates-strong-antitumor-activity-in-preclinical-study 2025-09-17T17:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-garetosmab-achieves-90-reduction-in-bone-formation-in-rare-disease-trial 2025-09-17T17:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/askbio-completes-enrollment-in-phase-1-gene-therapy-trial-for-rare-neurological-disease-msa-p 2025-09-17T17:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-s-temtokibart-meets-primary-endpoint-in-phase-2b-atopic-dermatitis-trial 2025-09-17T17:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/luxa-biotechnology-reports-significant-vision-gains-in-first-in-human-stem-cell-trial-for-dry-amd 2025-09-17T17:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/mapi-pharma-initiates-phase-i-ii-trial-for-once-monthly-cariprazine-depot-injection 2025-09-17T17:14:13+00:00 hourly 0.9 https://trial.medpath.com/news/arch-biopartners-acquires-novel-il-32-platform-for-chronic-kidney-disease-treatment 2025-09-17T17:13:37+00:00 hourly 0.9 https://trial.medpath.com/news/visionary-holdings-partners-with-yike-regenerative-medicine-to-advance-anti-aging-biotechnology 2025-09-17T17:13:34+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-pharma-s-tinostamustine-enters-phase-2-3-gbm-agile-trial-for-glioblastoma-treatment 2025-09-17T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/ollin-biosciences-emerges-with-100m-to-challenge-leading-eye-disease-treatments 2025-09-17T17:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-and-aditum-bio-launch-kalexo-bio-to-advance-novel-sirna-therapy-for-cardiovascular-disease 2025-09-17T17:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/first-digital-cbt-therapeutic-for-menopause-shows-significant-symptom-reduction-in-clinical-trial 2025-09-17T17:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drugs-alter-taste-perception-enhancing-sweetness-and-saltiness-to-support-appetite-control 2025-09-17T13:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/navigator-medicines-reports-positive-phase-1a-safety-data-for-dual-target-bispecific-antibody-nav-240 2025-09-17T13:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/brepocitinib-achieves-first-ever-positive-phase-3-results-in-dermatomyositis-setting-new-treatment-standard 2025-09-17T13:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/uk-secures-zero-tariff-us-deal-and-increases-medicine-investment-to-accelerate-patient-access-to-breakthrough-treatments 2025-09-17T13:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/amber-implants-receives-fda-510-k-clearance-for-vcfix-spinal-system-to-treat-vertebral-compression-fractures 2025-09-17T13:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/microbiotica-completes-recruitment-for-phase-1b-trial-of-microbiome-therapy-mb097-in-treatment-resistant-melanoma 2025-09-17T13:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-saphnelo-subcutaneous-formulation-meets-primary-endpoint-in-phase-iii-lupus-trial 2025-09-17T13:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/uhnm-becomes-first-uk-site-to-recruit-patient-for-biontech-s-phase-3-small-cell-lung-cancer-trial 2025-09-17T13:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/ernexa-therapeutics-to-present-breakthrough-erna-101-cell-therapy-data-at-aacr-ovarian-cancer-conference 2025-09-17T12:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/innate-pharma-advances-key-pipeline-assets-while-implementing-strategic-restructuring 2025-09-17T09:11:47+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-achieves-first-successful-car-t-cell-therapy-treatment-for-pediatric-acute-leukemia 2025-09-17T09:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-licenses-long-acting-monoclonal-antibody-tnx-4800-for-seasonal-lyme-disease-prevention 2025-09-17T09:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-s-povorcitinib-shows-sustained-efficacy-in-phase-3-hidradenitis-suppurativa-trials-through-24-weeks 2025-09-17T09:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-solutions-enhances-manufacturing-capabilities-with-advanced-bilayer-tablet-press-technology 2025-09-17T09:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letters-to-eli-lilly-novo-nordisk-and-hims-over-misleading-weight-loss-drug-advertising 2025-09-17T09:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/co-diagnostics-forms-joint-venture-with-saudi-arabian-partner-to-manufacture-pcr-diagnostics-platform 2025-09-17T09:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/scienture-s-arbli-becomes-first-fda-approved-ready-to-use-liquid-losartan-securing-major-market-access 2025-09-17T05:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/hightide-therapeutics-htd1801-achieves-primary-endpoint-in-phase-3-type-2-diabetes-trial 2025-09-17T05:11:25+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-s-tau-antibody-etalanetug-receives-fda-fast-track-designation-for-alzheimer-s-disease 2025-09-17T05:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/cytokinetics-raises-650-million-through-convertible-notes-to-fund-aficamten-commercial-launch 2025-09-17T01:15:09+00:00 hourly 0.9 https://trial.medpath.com/news/auravax-secures-gates-foundation-grant-for-nanosting-001-influenza-challenge-study 2025-09-17T01:13:26+00:00 hourly 0.9 https://trial.medpath.com/news/polypid-passes-fourth-consecutive-gmp-inspection-advances-d-plex100-toward-2026-nda-submission 2025-09-17T01:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/nxera-pharma-advances-novel-ep4-antagonist-htl0039732-to-phase-2a-trial-for-advanced-solid-tumors 2025-09-17T01:12:58+00:00 hourly 0.9 https://trial.medpath.com/news/british-columbia-opens-first-phase-1-clinical-trials-unit-for-non-oncology-treatments 2025-09-17T01:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-advances-osavampator-to-phase-3-following-positive-depression-trial-results 2025-09-17T01:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-commits-30-billion-u-s-investment-to-advance-respiratory-and-cancer-medicine-manufacturing 2025-09-17T01:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/ir-med-s-pressuresafe-technology-advances-through-clinical-trials-targeting-26-8b-pressure-injury-market 2025-09-16T21:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/utr-therapeutics-publishes-preclinical-data-for-first-in-class-c-myc-rna-therapeutic-utrxm1-18 2025-09-16T21:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-trial-confirms-shunt-surgery-benefits-for-older-adults-with-hydrocephalus 2025-09-16T21:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/blood-tests-show-promise-for-early-als-detection-years-before-symptoms-appear 2025-09-16T21:15:06+00:00 hourly 0.9 https://trial.medpath.com/news/yokogawa-and-repligen-partner-to-advance-real-time-bioprocess-monitoring-technology 2025-09-16T21:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/roche-integrates-ai-enabled-accu-chek-smartguide-cgm-with-mysugr-app-following-ce-mark-approval 2025-09-16T21:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-drug-patent-term-extensions-marking-new-era-for-pharmaceutical-ip-protection 2025-09-16T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/gout-drug-pipeline-expands-with-25-novel-therapies-as-companies-target-unmet-medical-needs 2025-09-16T21:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/cantoni-therapeutics-secures-funding-to-advance-novel-nnmt-inhibitor-for-obesity-treatment 2025-09-16T17:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-divests-historic-china-joint-venture-stake-to-focus-on-innovation 2025-09-16T17:16:51+00:00 hourly 0.9 https://trial.medpath.com/news/autolus-therapeutics-reports-promising-safety-profile-for-car-t-therapy-in-severe-lupus-patients 2025-09-16T17:16:18+00:00 hourly 0.9 https://trial.medpath.com/news/prt120-peanut-oral-immunotherapy-demonstrates-durable-3-year-remission-in-phase-2b-study 2025-09-16T17:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/gaiaso-appoints-dr-tracey-brown-as-ceo-to-advance-precision-radiopharmaceuticals-for-women-s-cancers 2025-09-16T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-advances-eb-003-depression-treatment-directly-to-ind-submission-following-fda-guidance 2025-09-16T17:14:19+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-shares-surge-16-5-following-exclusive-korean-licensing-deal-for-ocu400-gene-therapy 2025-09-16T17:14:13+00:00 hourly 0.9 https://trial.medpath.com/news/berlin-center-for-gene-and-cell-therapies-breaks-ground-creating-european-hub-for-advanced-therapeutics 2025-09-16T17:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/adaptimmune-s-tecelra-marks-first-engineered-cell-therapy-approval-for-solid-tumors-in-synovial-sarcoma 2025-09-16T17:13:56+00:00 hourly 0.9 https://trial.medpath.com/news/allrock-bio-secures-50-million-series-a-to-advance-first-in-class-pan-rock-inhibitor-for-pulmonary-hypertension 2025-09-16T17:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/aptevo-s-mipletamig-achieves-100-remission-rate-in-phase-1b-2-aml-trial 2025-09-16T17:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/dualitas-therapeutics-emerges-from-stealth-with-65m-series-a-to-advance-bispecific-antibody-pipeline 2025-09-16T17:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/nuclidium-s-copper-based-pet-tracer-shows-promise-in-phase-i-ii-trial-for-neuroendocrine-tumor-detection 2025-09-16T17:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/areteia-s-dexpramipexole-achieves-primary-endpoint-in-phase-iii-eosinophilic-asthma-trial 2025-09-16T17:10:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-crb-701-adc-for-recurrent-head-and-neck-cancer 2025-09-16T17:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/patensee-receives-fda-breakthrough-device-designation-for-ai-driven-hemodialysis-monitoring-system 2025-09-16T17:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-commits-5-billion-to-virginia-manufacturing-facility-for-bioconjugate-and-adc-production 2025-09-16T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-launches-next-generation-acid-blocker-tegoprazan-in-india-following-phase-iii-success 2025-09-16T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/metis-techbio-launches-ai-powered-nanoforge-platform-to-transform-drug-delivery 2025-09-16T17:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/cook-myosite-advances-phase-iii-cell-therapy-trial-for-chronic-fecal-incontinence-in-women 2025-09-16T13:14:02+00:00 hourly 0.9 https://trial.medpath.com/news/metabolic-surgery-demonstrates-superior-long-term-outcomes-over-glp-1-receptor-agonists-in-diabetes-and-obesity 2025-09-16T13:13:34+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-durvalumab-for-limited-stage-small-cell-lung-cancer-first-treatment-advance-in-over-30-years 2025-09-16T13:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/fluoguide-receives-fda-alignment-for-fg001-intraoperative-imaging-agent-in-high-grade-glioma 2025-09-16T13:12:31+00:00 hourly 0.9 https://trial.medpath.com/news/aprecia-partners-with-apprentice-io-to-scale-ai-powered-3d-pharmaceutical-manufacturing 2025-09-16T13:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/zyvet-launches-first-fda-approved-generic-phenylpropanolamine-for-canine-urinary-incontinence 2025-09-16T13:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-medical-device-for-asherman-syndrome-addressing-major-cause-of-female-infertility 2025-09-16T13:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/tenax-therapeutics-secures-european-patent-protection-for-levosimendan-in-ph-hfpef-through-2040 2025-09-16T13:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/aicuris-reports-positive-phase-2-results-for-pritelivir-in-refractory-hsv-infections-and-favorable-phase-1-safety-data-for-aic468 2025-09-16T09:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-biotech-in-advanced-licensing-talks-with-j-j-and-roche-for-experimental-cancer-drug 2025-09-16T09:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/ferroptosis-inducing-drug-auranofin-shows-promise-in-combination-with-chemotherapy-for-resistant-neuroblastoma 2025-09-16T09:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-for-apollo-tms-device-to-treat-major-depressive-disorder-in-adolescents 2025-09-16T09:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/race-oncology-discovers-novel-bisantrene-photoisomers-files-patent-applications-for-20-year-protection 2025-09-16T09:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-vyjuvek-label-for-home-use-and-all-ages-boosting-krystal-biotech-s-market-potential 2025-09-16T09:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/anacardio-completes-phase-2a-enrollment-for-heart-failure-drug-candidate-ac01 2025-09-16T09:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-modus-expands-patent-enforcement-campaign-with-lawsuit-against-indian-ai-retail-company-allerin-tech 2025-09-16T05:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/drug-hunter-secures-seed-investment-to-expand-knowledge-platform-for-pharmaceutical-r-d 2025-09-16T05:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-set-to-review-five-key-pediatric-and-adult-therapies-in-q4-2025 2025-09-16T05:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/race-oncology-secures-breakthrough-patent-protection-for-purified-bisantrene-cancer-drug 2025-09-16T05:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/crism-therapeutics-advances-toward-phase-2-glioblastoma-trial-despite-widening-losses 2025-09-16T05:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/turn-therapeutics-prepares-for-nasdaq-debut-with-focus-on-dermatology-and-infectious-disease-programs 2025-09-16T01:18:17+00:00 hourly 0.9 https://trial.medpath.com/news/altimmune-appoints-linda-richardson-as-chief-commercial-officer-ahead-of-pemvidutide-phase-3-mash-trial 2025-09-16T01:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/nyxoah-files-patent-infringement-lawsuit-against-inspire-medical-systems-over-sleep-apnea-devices 2025-09-16T01:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/indian-patent-office-revokes-novartis-vymada-patent-opening-door-for-generic-competition 2025-09-16T01:14:45+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-wegovy-shows-46-reduction-in-food-noise-and-improved-mental-health-in-real-world-survey 2025-09-16T01:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/mit-and-bidmc-teams-advance-novel-mrna-based-tuberculosis-vaccines-using-newly-identified-antigens 2025-09-16T01:13:55+00:00 hourly 0.9 https://trial.medpath.com/news/cook-medical-and-siemens-healthineers-launch-radiation-free-interventional-mri-suite-for-real-time-minimally-invasive-procedures 2025-09-16T01:13:39+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-analysis-reveals-new-adverse-events-for-fenfluramine-in-rare-epilepsy-syndromes 2025-09-15T21:13:52+00:00 hourly 0.9 https://trial.medpath.com/news/atyr-pharma-s-efzofitimod-fails-phase-3-trial-for-pulmonary-sarcoidosis 2025-09-15T21:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-shows-glp-1-receptor-agonists-effective-for-pediatric-obesity-and-type-2-diabetes 2025-09-15T21:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/smith-nephew-s-regeneten-bioinductive-implant-receives-aaos-strong-recommendation-following-65-reduction-in-rotator-cuff-re-tear-rates 2025-09-15T21:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/labconnect-and-omniscience-partner-to-launch-first-agentic-ai-platform-for-real-time-clinical-trial-lab-data-analysis 2025-09-15T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/cms-finalizes-third-round-of-medicare-drug-price-negotiations-with-expanded-orphan-drug-exclusions 2025-09-15T21:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/parexel-forms-strategic-ai-partnerships-to-accelerate-drug-development-and-clinical-trial-efficiency 2025-09-15T20:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/proteonic-launches-2g-unic-transposon-platform-for-enhanced-biologics-production 2025-09-15T17:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/federal-courts-uphold-state-340b-protection-laws-against-pharmaceutical-challenges 2025-09-15T17:30:24+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-challenges-rhode-island-s-340b-drug-pricing-law-in-federal-court 2025-09-15T17:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/serine-free-diet-shows-promise-in-slowing-glioblastoma-growth-and-enhancing-treatment-response 2025-09-15T17:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/mycenax-biotech-and-spera-pharma-form-strategic-alliance-to-enhance-adc-manufacturing-capabilities 2025-09-15T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-s-symvess-demonstrates-92-patency-rate-in-hospital-acquired-vascular-complications-study 2025-09-15T17:25:05+00:00 hourly 0.9 https://trial.medpath.com/news/lindis-blood-care-s-catuvab-device-achieves-100-tumor-cell-removal-in-pivotal-cancer-surgery-study 2025-09-15T17:23:51+00:00 hourly 0.9 https://trial.medpath.com/news/sohm-secures-south-korean-patent-for-crispr-based-gene-editing-platform-targeting-car-t-therapy-development 2025-09-15T17:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/gyala-therapeutics-advances-first-in-class-cd84-targeting-car-t-therapy-with-eur3-million-funding-for-aml-and-t-all-treatment 2025-09-15T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/biparametric-mri-proves-noninferior-to-standard-multiparametric-mri-for-prostate-cancer-detection-in-prime-trial 2025-09-15T17:22:29+00:00 hourly 0.9 https://trial.medpath.com/news/avalyn-pharma-unveils-aura-ipf-phase-2-trial-design-for-inhaled-nintedanib-at-ers-congress-2025 2025-09-15T17:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/labcorp-completes-225-million-acquisition-of-bioreference-health-s-oncology-testing-assets 2025-09-15T17:21:56+00:00 hourly 0.9 https://trial.medpath.com/news/made-scientific-partners-with-basilard-biotech-to-advance-nanomechanical-gene-delivery-platform-for-cell-therapies 2025-09-15T17:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/conceivable-life-sciences-raises-50-million-series-a-to-commercialize-ai-powered-automated-ivf-laboratory 2025-09-15T17:20:39+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-vraylar-achieves-full-provincial-coverage-in-canada-with-alberta-reimbursement-approval 2025-09-15T17:20:29+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-achieves-commercial-manufacturing-milestone-for-rdeb-cell-therapy-cordstromtm 2025-09-15T17:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-presents-phase-3-data-for-seltorexant-in-major-depressive-disorder-at-2025-psych-congress 2025-09-15T17:18:07+00:00 hourly 0.9 https://trial.medpath.com/news/emergent-biosolutions-secures-17-million-barda-contract-for-smallpox-antiviral-tembexa-oral-suspension 2025-09-15T17:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/fire-trial-shows-supraflex-cruz-stent-reduces-cardiovascular-events-in-elderly-heart-attack-patients 2025-09-15T17:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/cadrenal-therapeutics-acquires-exithera-s-factor-xia-inhibitor-portfolio-in-15m-deal 2025-09-15T17:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/rona-therapeutics-files-ind-for-rn3161-novel-sirna-targeting-inhbe-for-obesity-treatment 2025-09-15T17:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-to-present-phase-2b-icotrokinra-data-for-ulcerative-colitis-at-european-gastroenterology-week 2025-09-15T17:15:11+00:00 hourly 0.9 https://trial.medpath.com/news/renalytix-partners-with-tempus-ai-to-expand-access-to-fda-approved-kidney-disease-risk-test 2025-09-15T17:14:57+00:00 hourly 0.9 https://trial.medpath.com/news/argo-biopharma-advances-sirna-therapy-bw-40202-to-phase-ii-trial-for-paroxysmal-nocturnal-hemoglobinuria 2025-09-15T17:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/biocartis-receives-fda-approval-for-first-fully-automated-companion-diagnostic-test-for-colorectal-cancer 2025-09-15T17:13:58+00:00 hourly 0.9 https://trial.medpath.com/news/modular-medical-receives-irb-approval-for-pivot-insulin-delivery-system-feasibility-study 2025-09-15T17:13:56+00:00 hourly 0.9 https://trial.medpath.com/news/biostar-pharma-initiates-two-phase-ii-iii-trials-for-utidelone-capsule-in-gastric-and-ovarian-cancers 2025-09-15T17:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-s-glac-biotech-receives-fda-gras-approval-for-probiotic-strain-cp-9-expanding-infant-nutrition-portfolio 2025-09-15T17:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/sagent-pharmaceuticals-enters-8-6-billion-ophthalmic-market-with-travoprost-launch 2025-09-15T17:11:39+00:00 hourly 0.9 https://trial.medpath.com/news/proofpilot-acquires-lokavant-to-enhance-clinical-trial-performance-with-ai-powered-predictive-analytics 2025-09-15T17:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/worldwide-clinical-trials-appoints-alistair-macdonald-as-new-ceo-following-peter-benton-s-retirement 2025-09-15T17:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/uci-mind-receives-18-million-nih-grant-to-establish-first-trial-ready-cohort-for-late-dementia 2025-09-15T17:11:14+00:00 hourly 0.9 https://trial.medpath.com/news/icecure-medical-advances-cryoablation-technology-with-patent-approval-and-regulatory-clearance-for-xsense-system 2025-09-15T17:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/b-braun-completes-full-acquisition-of-true-digital-surgery-to-advance-digital-microsurgery-technology 2025-09-15T14:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-launches-pivotal-trial-testing-personalized-pacing-therapy-for-heart-failure-patients 2025-09-15T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ondine-biomedical-s-steriwave-technology-shows-99-9-efficacy-against-drug-resistant-c-auris-as-european-cases-surge-67 2025-09-15T13:13:45+00:00 hourly 0.9 https://trial.medpath.com/news/catalym-strengthens-leadership-team-to-advance-visugromab-through-late-stage-development 2025-09-15T13:13:01+00:00 hourly 0.9 https://trial.medpath.com/news/kodiak-sciences-ksi-101-demonstrates-62-vision-improvement-in-phase-1b-mesi-trial 2025-09-15T13:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/genflow-biosciences-signs-cdas-with-animal-health-companies-to-advance-sirt6-gene-therapy-platform 2025-09-15T13:12:50+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-partners-with-kwangdong-for-ocu400-gene-therapy-in-korea-with-7-5m-upfront-deal 2025-09-15T13:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-reports-complete-resolution-of-esophageal-varices-in-decompensated-cirrhosis-patient-treated-with-namodenoson 2025-09-15T13:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/som-biotech-secures-european-orphan-drug-designation-for-huntington-s-disease-therapy-som3355 2025-09-15T13:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/international-research-team-secures-800000-to-advance-first-potentially-regenerative-multiple-sclerosis-treatment 2025-09-15T13:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/curatis-advances-c-ptbe-01-toward-phase-iii-trial-following-positive-fda-meeting 2025-09-15T13:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/dexcom-unveils-smart-basal-feature-and-presents-clinical-evidence-at-easd-2025 2025-09-15T13:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/novocure-s-optune-lua-receives-japanese-approval-for-advanced-nsclc-treatment 2025-09-15T13:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-secures-ce-mark-for-recell-go-expanding-burn-treatment-access-across-europe 2025-09-15T09:14:09+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-advances-australian-discovered-kat6-inhibitor-pf-07248144-to-phase-3-trial-for-hr-her2-metastatic-breast-cancer 2025-09-15T09:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/qlife-advances-two-home-diagnostic-tests-for-heart-failure-into-clinical-trials 2025-09-15T09:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/seven-real-world-studies-demonstrate-nefecon-s-efficacy-in-iga-nephropathy-treatment-across-diverse-patient-populations 2025-09-15T06:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/everbridge-group-secures-exclusive-japanese-market-partnership-with-cosmotec-for-medical-device-commercialization 2025-09-15T06:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/phrontline-biopharma-initiates-phase-1-trial-for-tj101-dual-target-adc-in-solid-tumors 2025-09-15T04:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/cleo-diagnostics-receives-positive-fda-feedback-for-ovarian-cancer-blood-test-advancing-toward-us-approval 2025-09-15T04:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/lion-tcr-receives-fda-ind-clearance-for-first-in-class-tcr-t-therapy-targeting-chronic-hepatitis-b 2025-09-15T04:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/agios-pharmaceuticals-faces-securities-fraud-investigation-following-fda-delay-of-pyrukynd-approval 2025-09-15T01:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/nurix-therapeutics-advances-bexobrutideg-phase-iii-program-and-expands-protein-degrader-pipeline 2025-09-14T21:14:05+00:00 hourly 0.9 https://trial.medpath.com/news/cocrystal-pharma-advances-antiviral-pipeline-with-13m-funding-cdi-988-enters-phase-1b-human-challenge-study 2025-09-14T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/monopar-s-alxn1840-shows-sustained-neurological-benefits-in-long-term-wilson-disease-study 2025-09-14T17:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-hiv-antibody-04-a06-neutralizes-98-5-of-viral-strains-in-preclinical-studies 2025-09-14T17:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/globe-biotech-secures-first-us-patent-for-bangladesh-with-single-dose-covid-19-mrna-vaccine 2025-09-14T13:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-receives-usfda-clearance-for-api-manufacturing-facilities-following-may-inspection 2025-09-14T13:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/indian-researchers-develop-cassava-starch-patches-for-oral-cancer-and-leukoplakia-treatment 2025-09-14T09:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-approves-phase-i-trial-for-jeevan-scientific-s-bevacizumab-biosimilar-in-india 2025-09-14T09:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-partners-with-asian-hospital-to-expand-access-to-rare-disease-treatments-in-philippines 2025-09-14T05:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/novocure-s-optune-lua-receives-fda-approval-for-metastatic-non-small-cell-lung-cancer-extending-survival-by-3-3-months 2025-09-14T05:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/indian-pharma-companies-leverage-fda-505-b-2-pathway-to-create-differentiated-generics-with-merck-support 2025-09-14T01:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-and-russia-sign-major-biopharmaceutical-technology-transfer-agreement-for-advanced-drug-production 2025-09-14T01:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/lila-sciences-achieves-unicorn-status-with-235m-funding-for-ai-driven-drug-discovery-platform 2025-09-14T01:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-stock-deemed-undervalued-following-recent-fda-approval-and-market-decline 2025-09-14T01:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-develop-revolutionary-bone-02-adhesive-that-heals-fractures-in-three-minutes 2025-09-13T21:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-stock-deemed-undervalued-following-recent-fda-approval-despite-20-8-annual-gains 2025-09-13T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/apollo-hospitals-invests-rs-573-crore-in-advanced-proton-therapy-oncology-center-in-gurugram 2025-09-13T17:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-draft-guidance-on-non-opioid-pain-therapies-could-accelerate-apitox-development-for-osteoarthritis 2025-09-13T17:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/verona-pharma-and-vertex-pharmaceuticals-show-divergent-valuation-patterns-following-recent-fda-approvals 2025-09-13T17:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/alligator-bioscience-presents-promising-preclinical-data-for-ator-4066-bispecific-antibody-at-cicon25 2025-09-13T13:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-lotus-study-shows-sustained-efficacy-of-daybue-in-rett-syndrome-patients-over-12-months 2025-09-13T13:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/mallinckrodt-wins-9-5m-patent-infringement-award-in-nitric-oxide-therapy-case 2025-09-13T10:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/triastek-opens-world-s-largest-3d-printed-pharmaceutical-facility-in-china-targets-300-million-tablets-annually 2025-09-13T09:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-analysis-reveals-cardiac-failure-risk-varies-significantly-among-breast-cancer-therapies 2025-09-13T09:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/fore-biotherapeutics-reports-durable-clinical-benefit-with-plixorafenib-in-braf-altered-thyroid-cancers 2025-09-13T05:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/yoltech-therapeutics-secures-45-million-series-b-funding-to-advance-in-vivo-gene-editing-pipeline 2025-09-13T05:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/musc-launches-clinical-trial-for-heart-safe-triple-negative-breast-cancer-treatment 2025-09-13T05:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bispecific-antibody-combinations-show-promise-in-indolent-lymphoma-treatment 2025-09-13T02:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/agios-mitapivat-receives-positive-chmp-opinion-for-thalassemia-treatment-in-europe 2025-09-13T01:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/uci-health-s-stopgap-ii-trial-advances-to-national-phase-for-advanced-gastric-cancer-treatment 2025-09-13T01:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/rybrevant-plus-lazcluze-combination-demonstrates-superior-overall-survival-in-first-line-egfr-mutated-nsclc 2025-09-13T01:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/uni-bio-science-group-partners-with-kexing-biopharm-to-expand-osteoporosis-treatment-bogutai-r-to-six-international-markets 2025-09-13T01:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/fermenta-biotech-secures-patent-for-plant-based-vitamin-d3-production-technology 2025-09-12T21:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/australian-court-denies-preliminary-injunction-against-sandoz-aflibercept-biosimilar-launch 2025-09-12T21:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/nevian-lifescience-launches-first-locally-manufactured-novartis-medicine-following-bangladesh-acquisition 2025-09-12T21:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/oncotelic-therapeutics-reports-progress-across-six-late-stage-drug-programs-in-oncology-and-rare-diseases 2025-09-12T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/novel-pcsk9-inhibitor-recaticimab-shows-54-ldl-cholesterol-reduction-in-phase-3-trial-for-familial-hypercholesterolemia 2025-09-12T21:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/zoetis-receives-eu-regulatory-nod-for-first-long-acting-feline-osteoarthritis-pain-treatment 2025-09-12T21:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-plans-to-present-data-linking-covid-19-vaccines-to-25-pediatric-deaths-at-cdc-advisory-meeting 2025-09-12T21:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/simris-biologics-secures-eur200k-grant-to-develop-novel-microcystin-based-adc-payloads-for-cancer-therapy 2025-09-12T17:18:27+00:00 hourly 0.9 https://trial.medpath.com/news/alx-oncology-appoints-barbara-klencke-as-interim-chief-medical-officer-to-advance-cancer-pipeline 2025-09-12T17:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/galimedix-therapeutics-completes-phase-1-trial-of-oral-alzheimer-s-drug-gal-101 2025-09-12T17:16:29+00:00 hourly 0.9 https://trial.medpath.com/news/gelteq-achieves-first-u-s-commercial-milestone-with-partner-s-nutraceutical-product-launch 2025-09-12T17:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/pulnovo-medical-secures-fda-ide-approvals-for-padn-system-clinical-trials-with-cms-coverage 2025-09-12T17:11:36+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-s-ateganosine-shows-promising-efficacy-in-phase-ii-nsclc-trial 2025-09-12T17:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/china-announces-national-hpv-vaccination-program-as-domestic-nine-valent-vaccine-launches 2025-09-12T13:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-moves-to-eliminate-expert-advisory-panels-for-individual-drug-reviews-under-trump-administration 2025-09-12T13:11:29+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-to-present-phase-3-teton-2-data-for-inhaled-treprostinil-in-idiopathic-pulmonary-fibrosis-at-ers-congress 2025-09-12T13:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/allterum-therapeutics-receives-fda-clearance-for-4a10-antibody-therapy-in-pediatric-leukemia 2025-09-12T13:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-advances-novel-aml-therapies-and-unveils-breakthrough-research-at-ash-2025 2025-09-12T13:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-shows-anlotinib-improves-survival-and-response-rates-in-nsclc-brain-metastases 2025-09-12T13:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/inflammasome-therapeutics-k8-implant-reduces-geographic-atrophy-lesion-growth-by-53-in-phase-i-trial 2025-09-12T09:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/sophont-raises-9-22-million-to-develop-multimodal-ai-platform-for-medical-diagnosis-and-drug-discovery 2025-09-12T09:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/polyrizon-s-intranasal-barrier-technology-shows-promise-against-respiratory-viruses-and-allergens 2025-09-12T07:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/achieve-life-sciences-appoints-dr-mark-rubinstein-as-interim-cmo-amid-cytisinicline-fda-review 2025-09-12T05:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/selinexor-triplet-therapy-shows-significant-survival-benefit-in-pi-naive-multiple-myeloma-patients 2025-09-12T05:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/world-gu-2025-highlights-advances-in-variant-histology-management-and-community-oncology-care-for-genitourinary-cancers 2025-09-12T02:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-appoints-former-eli-lilly-executive-rhonda-pacheco-to-lead-u-s-operations 2025-09-12T01:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-scientists-win-prestigious-lasker-award-for-revolutionary-cystic-fibrosis-treatment 2025-09-12T01:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-secures-1-3-billion-us-manufacturing-deal-amid-trade-policy-uncertainty 2025-09-12T01:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-inaugurates-first-us-manufacturing-facility-in-new-jersey-with-30-million-investment 2025-09-12T01:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-acquires-icometrix-to-strengthen-brain-mri-analysis-capabilities-for-alzheimer-s-drug-monitoring 2025-09-12T01:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-committee-establishes-framework-for-ai-powered-mental-health-chatbots 2025-09-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-fully-digital-adhd-diagnostic-tool-validated-in-peer-reviewed-study 2025-09-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/odyssey-therapeutics-raises-213m-series-d-to-advance-autoimmune-disease-pipeline-after-shelving-ipo-plans 2025-09-11T22:12:46+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-withdraws-dea-marijuana-rules-clearing-path-for-fda-compliant-cannabis-trials 2025-09-11T21:15:15+00:00 hourly 0.9 https://trial.medpath.com/news/intercept-pharmaceuticals-withdraws-ocaliva-from-u-s-market-following-fda-safety-directive 2025-09-11T21:14:15+00:00 hourly 0.9 https://trial.medpath.com/news/gene-solutions-secures-patent-for-novel-mitochondrial-therapy-platform-targeting-neurological-diseases 2025-09-11T21:12:24+00:00 hourly 0.9 https://trial.medpath.com/news/ose-immunotherapeutics-completes-enrollment-in-phase-2-trial-testing-tedopi-cancer-vaccine-combinations-for-nsclc 2025-09-11T21:11:33+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-develop-nano-tagging-robot-for-enhanced-cancer-immunotherapy 2025-09-11T21:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-ai-powered-bone-health-technologies-for-orthopedic-care 2025-09-11T21:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/federal-appeals-court-upholds-medicare-drug-price-negotiations-for-novo-nordisk-insulin-products 2025-09-11T21:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-national-drug-price-negotiation-policy-dramatically-improves-access-to-innovative-medicines-while-reducing-costs-by-up-to-78 2025-09-11T21:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/amd-partners-with-oracle-and-absci-to-accelerate-ai-driven-drug-discovery-using-advanced-gpu-technology 2025-09-11T21:10:06+00:00 hourly 0.9 https://trial.medpath.com/news/large-taiwanese-study-reveals-mixed-safety-profile-for-long-term-atropine-use-in-childhood-myopia-treatment 2025-09-11T21:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-receives-fda-510-k-clearance-for-enhanced-cardiac-imaging-platform-with-t1-and-t2-mapping-capabilities 2025-09-11T21:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/n-power-medicine-and-viecure-partner-to-transform-clinical-trial-access-in-community-oncology 2025-09-11T21:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-receives-fda-approval-for-generic-sodium-oxybate-breaking-jazz-pharmaceuticals-monopoly-in-narcolepsy-treatment 2025-09-11T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/acne-drug-isotretinoin-shows-promise-for-treating-male-infertility-in-small-study 2025-09-11T21:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/energous-completes-5-million-financing-round-to-advance-wireless-power-technology 2025-09-11T20:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/actuate-therapeutics-raises-17-25-million-to-advance-gsk-3b-inhibitor-for-difficult-to-treat-cancers 2025-09-11T20:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/teleflex-initiates-dubstent-diabetes-trial-testing-dual-device-strategy-for-diabetic-patients-undergoing-pci 2025-09-11T17:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/nutriband-raises-5-3-million-through-warrant-exercises-to-advance-aversa-fentanyl-abuse-deterrent-patch-toward-fda-submission 2025-09-11T17:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/fibrobiologics-reports-breakthrough-results-for-single-dose-fibroblast-spheroid-therapy-in-chronic-psoriasis 2025-09-11T17:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/maze-therapeutics-mze782-shows-42-fold-increase-in-phenylalanine-excretion-in-phase-1-trial-for-pku-and-ckd 2025-09-11T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/profusa-partners-with-nvidia-to-develop-ai-powered-continuous-biomarker-monitoring-portal 2025-09-11T17:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/medicines-discovery-catapult-and-crown-bioscience-form-strategic-alliance-to-accelerate-radiopharmaceutical-development 2025-09-11T17:17:51+00:00 hourly 0.9 https://trial.medpath.com/news/intercept-pharmaceuticals-voluntarily-withdraws-ocaliva-from-us-market-following-fda-request 2025-09-11T17:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/roivant-sciences-gains-orphan-drug-designation-in-japan-for-mosliciguat-in-pulmonary-hypertension 2025-09-11T17:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/charles-river-laboratories-forms-strategic-oncology-alliances-to-accelerate-cancer-immunotherapy-development 2025-09-11T17:14:41+00:00 hourly 0.9 https://trial.medpath.com/news/former-fda-hematologic-malignancies-leader-nicholas-richardson-joins-precision-for-medicine-as-vp-clinical-development 2025-09-11T17:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/absci-partners-with-oracle-and-amd-to-accelerate-ai-driven-drug-discovery-platform 2025-09-11T17:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/nanonewron-secures-2-5m-nih-grant-to-advance-blood-brain-barrier-crossing-tnf-alpha-inhibitor-for-alzheimer-s-disease 2025-09-11T13:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-files-patent-lawsuit-against-ionis-over-plozasiran-fcs-treatment 2025-09-11T13:15:31+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-s-envista-envy-iol-demonstrates-superior-visual-performance-in-pivotal-clinical-trial 2025-09-11T13:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-capvaxive-shows-superior-immune-response-in-high-risk-children-and-adolescents 2025-09-11T13:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/radiomedix-and-vect-horus-initiate-first-in-human-trial-of-blood-brain-barrier-crossing-radiotracer-for-glioblastoma-and-pancreatic-cancer 2025-09-11T13:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-restructures-global-operations-exits-27-markets-through-strategic-partnership-model 2025-09-11T13:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/apple-watch-receives-fda-approval-for-hypertension-detection-feature-expected-to-identify-over-one-million-undiagnosed-cases 2025-09-11T13:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/musc-hollings-cancer-center-launches-automain-trial-testing-repurposed-drugs-for-recurrent-ovarian-cancer 2025-09-11T11:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/minnesota-develops-innovative-learning-health-care-community-model-to-bridge-research-practice-gap 2025-09-11T10:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-laboratories-acquires-johnson-johnson-s-stugeron-brand-for-50-5-million-to-expand-cns-portfolio 2025-09-11T09:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/tg-therapeutics-to-present-six-year-briumvi-data-at-ectrims-2025-showcasing-long-term-multiple-sclerosis-treatment-outcomes 2025-09-11T09:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/camp4-therapeutics-secures-100-million-financing-to-advance-first-in-class-syngap1-treatment 2025-09-11T09:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-advances-two-breakthrough-rnai-therapeutics-into-clinical-trials 2025-09-11T09:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/tagworks-pharmaceuticals-advances-tgw101-to-third-dose-level-in-phase-1-trial-for-solid-tumors 2025-09-11T09:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/bioxodes-reports-promising-phase-2a-results-for-biox-101-in-intracerebral-hemorrhage-treatment 2025-09-11T09:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/teva-and-medincell-s-long-acting-risperidone-injection-expands-global-reach-with-canadian-approval 2025-09-11T09:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-health-ventures-makes-inaugural-investment-in-delix-therapeutics-non-hallucinogenic-depression-treatment 2025-09-11T09:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-antioxidants-reverse-t-cell-exhaustion-by-protecting-telomeres-in-cancer-therapy 2025-09-11T05:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/xingimaging-and-synusight-receive-3-84m-grant-to-advance-first-a-synuclein-pet-tracer-for-parkinson-s-disease 2025-09-11T05:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/capsida-suspends-gene-therapy-trial-after-first-patient-dies-following-treatment-for-rare-stxbp1-disorder 2025-09-11T05:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-imdelltra-receives-fda-approval-and-guideline-upgrade-rocatinlimab-phase-3-data-awaited 2025-09-11T05:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/precision-tools-transform-breast-cancer-survivorship-care-as-patients-navigate-post-treatment-challenges 2025-09-11T05:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/dewpoint-therapeutics-secures-series-d-funding-to-advance-novel-condensate-modulator-for-gastric-cancer 2025-09-11T01:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-major-crackdown-on-misleading-pharmaceutical-advertising-under-trump-administration 2025-09-11T01:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/nih-study-shows-jail-based-opioid-treatment-reduces-fatal-overdoses-by-52-and-improves-post-release-outcomes 2025-09-11T01:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/sagimet-s-denifanstat-shows-significant-anti-fibrotic-benefits-in-advanced-mash-patients-at-aasld-2025 2025-09-11T01:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/neurosense-s-primec-shows-enhanced-neuroplasticity-in-alzheimer-s-patient-derived-neurons 2025-09-11T01:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-maine-researchers-develop-sustainable-wood-based-production-method-for-key-pharmaceutical-building-block 2025-09-11T01:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/design-therapeutics-appoints-former-gw-pharmaceuticals-ceo-justin-gover-to-board-of-directors 2025-09-11T01:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/bassett-research-institute-receives-12-million-pcori-grant-to-study-kidney-effects-of-common-antibiotic-combination 2025-09-11T01:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/apozeal-pharmaceuticals-secures-4-1m-investment-to-expand-generic-drug-manufacturing-in-pennsylvania 2025-09-11T01:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/centinel-spine-achieves-fda-approval-for-two-level-cervical-disc-replacement-with-record-breaking-clinical-success-rate 2025-09-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fibrobiologics-reports-breakthrough-in-bone-marrow-organoid-platform-for-cancer-and-immune-system-regeneration 2025-09-10T21:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/lutetium-lu-177-dotatate-shows-promise-in-metastatic-bronchopulmonary-neuroendocrine-tumors 2025-09-10T21:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/basal-cell-neoplasm-drug-pipeline-expands-with-22-companies-developing-novel-therapies 2025-09-10T21:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/jak1-inhibitors-show-superior-antipruritic-effects-over-il-13-antibodies-in-atopic-dermatitis 2025-09-10T21:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/nurexone-s-exopten-shows-promising-results-in-spinal-cord-injury-and-glaucoma-preclinical-studies 2025-09-10T21:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/merck-abandons-ps1-billion-london-research-centre-cuts-125-uk-science-jobs 2025-09-10T21:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/france-approves-compassionate-access-for-agenus-bot-bal-immunotherapy-in-refractory-mss-colorectal-cancer 2025-09-10T21:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/kfshrc-achieves-first-locally-manufactured-car-t-cell-treatment-in-saudi-arabia 2025-09-10T21:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/new-retinal-formulation-retaxome-shows-enhanced-tolerability-in-clinical-studies 2025-09-10T21:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/merck-halts-u-k-research-operations-abandons-london-facility-over-nhs-drug-pricing-disputes 2025-09-10T21:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/truleaf-achieves-first-in-human-implantation-of-revolutionary-catheter-based-heart-valve-system 2025-09-10T21:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/500000-grant-expands-phase-2-trial-of-wokvac-breast-cancer-vaccine-at-university-of-washington 2025-09-10T21:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/dianthus-therapeutics-soars-50-following-positive-phase-2-results-for-myasthenia-gravis-drug 2025-09-10T17:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/innorna-completes-phase-ii-enrollment-for-world-s-first-bivalent-rsv-mrna-vaccine 2025-09-10T17:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/imaging-endpoints-files-patent-for-ai-enhanced-imaging-review-charter-system-to-optimize-oncology-trials 2025-09-10T17:29:43+00:00 hourly 0.9 https://trial.medpath.com/news/ppar-gamma-pathway-modulation-enhances-nectin4-targeted-car-t-therapy-for-bladder-cancer 2025-09-10T17:29:16+00:00 hourly 0.9 https://trial.medpath.com/news/exact-sciences-launches-cancerguard-multi-cancer-blood-test-for-early-detection 2025-09-10T17:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/sublingual-edaravone-dexborneol-tablet-shows-superior-cost-effectiveness-for-acute-ischemic-stroke-treatment 2025-09-10T17:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/kadimastem-and-nls-pharmaceutics-clear-final-sec-hurdle-for-merger-creating-newcelx 2025-09-10T17:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/galectin-therapeutics-belapectin-shows-49-reduction-in-liver-varices-stock-hits-52-week-high 2025-09-10T17:25:54+00:00 hourly 0.9 https://trial.medpath.com/news/cuspai-raises-100-million-series-a-to-accelerate-ai-driven-materials-discovery-for-healthcare-and-sustainability 2025-09-10T17:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/tepotinib-shows-high-frequency-of-adverse-events-but-manageable-safety-profile-in-met-exon-14-altered-nsclc 2025-09-10T17:24:40+00:00 hourly 0.9 https://trial.medpath.com/news/symeres-acquires-dgr-pharma-to-strengthen-integrated-drug-development-services 2025-09-10T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/euda-health-signs-letter-of-intent-to-acquire-ipsc-platform-developer-go-posb-for-regenerative-medicine-expansion 2025-09-10T17:21:38+00:00 hourly 0.9 https://trial.medpath.com/news/mednovo-doses-first-patient-in-phase-iii-trial-of-lutetium-177-radiotherapy-for-neuroendocrine-tumors 2025-09-10T17:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/aurora-2-study-shows-no-increased-nephrotoxicity-with-voclosporin-in-lupus-nephritis-after-18-months 2025-09-10T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/greenwich-lifesciences-glsi-100-receives-fda-fast-track-designation-for-her2-positive-breast-cancer 2025-09-10T17:19:54+00:00 hourly 0.9 https://trial.medpath.com/news/dermata-therapeutics-pivots-from-prescription-to-otc-dermatology-products-following-successful-phase-3-acne-trial 2025-09-10T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/pmv-pharma-s-rezatapopt-demonstrates-33-response-rate-in-phase-2-trial-for-tp53-y220c-solid-tumors 2025-09-10T17:19:19+00:00 hourly 0.9 https://trial.medpath.com/news/orimed-pharma-launches-prsolufy-first-liquid-aripiprazole-solution-in-canada 2025-09-10T17:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-launches-ai-powered-clinical-trial-financial-suite-to-automate-site-payments-and-budget-management 2025-09-10T17:18:18+00:00 hourly 0.9 https://trial.medpath.com/news/greenwich-lifesciences-glsi-100-receives-fda-fast-track-designation-for-her2-positive-breast-cancer-prevention 2025-09-10T13:15:04+00:00 hourly 0.9 https://trial.medpath.com/news/celcuity-secures-500-million-credit-facility-following-positive-phase-3-data-for-gedatolisib-in-advanced-breast-cancer 2025-09-10T13:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/aphaia-pharma-advances-oral-glucose-based-obesity-treatment-with-second-phase-2-trial 2025-09-10T13:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/cascade-bio-raises-6m-to-advance-cell-free-biocatalyst-technology-for-industrial-manufacturing 2025-09-10T13:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-obagi-saypha-magiq-injectable-hyaluronic-acid-filler-marking-waldencast-s-entry-into-us-dermal-filler-market 2025-09-10T13:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/diamyd-medical-secures-key-patents-for-precision-medicine-approach-to-type-1-diabetes-treatment 2025-09-10T13:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/revelation-biosciences-gemini-shows-promise-in-phase-1b-trial-for-chronic-kidney-disease 2025-09-10T13:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/cutiss-raises-eur57-9m-series-c-to-advance-phase-3-trial-of-personalized-skin-graft-therapy 2025-09-10T13:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/triple-negative-breast-cancer-pipeline-expands-with-170-emerging-therapies-as-companies-advance-novel-treatment-approaches 2025-09-10T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/vedabio-secures-40m-series-a-and-strategic-partnership-with-siemens-healthineers-for-crispr-diagnostics-platform 2025-09-10T09:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-sobi-s-nasp-biologics-license-application-for-uncontrolled-gout-treatment 2025-09-10T09:17:07+00:00 hourly 0.9 https://trial.medpath.com/news/resolution-therapeutics-strengthens-leadership-team-with-key-executive-appointments-as-rtx001-advances-in-clinical-trials 2025-09-10T08:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/iga-nephropathy-pipeline-shows-strong-growth-with-30-therapies-in-development-across-multiple-clinical-stages 2025-09-10T07:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-bylvay-for-alagille-syndrome-treatment-marking-first-dual-indication-rare-disease-therapy 2025-09-10T06:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/beckman-coulter-life-sciences-partners-with-hse-ag-to-automate-nucleic-acid-quantification-workflows 2025-09-10T06:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/varian-secures-first-european-approval-for-knee-arthritis-embolization-device 2025-09-10T06:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/scenic-biotech-appoints-dr-roland-w-burli-as-chief-scientific-officer-to-advance-modifier-therapy-pipeline 2025-09-10T06:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-koala-chlamydia-vaccine-receives-regulatory-approval-in-australia 2025-09-10T04:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/qiagen-receives-fda-clearance-for-qiastat-dx-rise-system-launches-globally-across-100-countries 2025-09-10T01:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/failed-als-drug-biib078-reached-target-but-failed-to-halt-disease-progression-emory-study-reveals 2025-09-10T01:16:43+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-libtayo-combination-therapy-demonstrates-19-4-five-year-survival-rate-in-advanced-lung-cancer 2025-09-10T01:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/paloma-2-study-confirms-efficacy-of-subcutaneous-amivantamab-in-egfr-exon-20-insertion-nsclc 2025-09-10T01:14:02+00:00 hourly 0.9 https://trial.medpath.com/news/wheeler-bio-partners-with-pharmefex-to-enhance-modularcmc-platform-for-ind-submissions 2025-09-10T01:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/scribe-therapeutics-demonstrates-breakthrough-crispr-therapy-for-cardiovascular-disease-with-90-lp-a-reduction 2025-09-10T01:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/nih-recover-tlc-launches-second-round-of-long-covid-clinical-trials-testing-glp-1-drugs-and-other-interventions 2025-09-10T01:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/analog-pharma-canada-launches-generic-pregnancy-nausea-treatment-in-canadian-market 2025-09-10T01:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/sunobinop-shows-promising-results-in-phase-1b-trial-for-interstitial-cystitis-bladder-pain-syndrome 2025-09-10T01:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/dz-002-cancer-therapy-advances-to-phase-2-trials-for-pancreatic-cancer-treatment 2025-09-10T01:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/wearable-devices-secures-patent-for-ai-powered-voice-and-gesture-control-technology 2025-09-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nurexone-secures-u-s-patent-for-proprietary-exosome-manufacturing-technology 2025-09-09T21:20:02+00:00 hourly 0.9 https://trial.medpath.com/news/pakistan-drug-authority-orders-immediate-recall-of-contaminated-metronidazole-infusion-over-bacterial-endotoxin-contamination 2025-09-09T21:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/delaware-court-rules-against-novo-nordisk-in-wegovy-patent-case-highlighting-challenges-in-method-of-treatment-claims 2025-09-09T21:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/circulating-tumor-dna-monitoring-enables-personalized-immunotherapy-in-limited-stage-small-cell-lung-cancer 2025-09-09T21:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/breakwater-study-reveals-ctdna-clearance-predicts-survival-in-braf-v600e-mutant-colorectal-cancer 2025-09-09T21:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/tspo-biomarker-shows-promise-for-early-alzheimer-s-detection-years-before-symptom-onset 2025-09-09T21:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/topcon-healthcare-invests-in-senseye-s-ai-powered-mental-health-diagnostic-platform-using-ocular-biomarkers 2025-09-09T21:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/lgc-group-opens-100-million-organic-chemistry-synthesis-center-in-canada-to-expand-global-drug-discovery-support 2025-09-09T21:15:04+00:00 hourly 0.9 https://trial.medpath.com/news/brief-anesthesia-shows-no-short-term-neurodevelopmental-risk-in-infants-under-2-years 2025-09-09T21:14:57+00:00 hourly 0.9 https://trial.medpath.com/news/icer-reverses-position-on-glp-1-obesity-drugs-finds-cost-effectiveness-despite-budget-concerns 2025-09-09T21:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/iregene-therapeutics-raises-40m-series-b-following-fda-fast-track-designation-for-parkinson-s-cell-therapy 2025-09-09T21:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-allergen-blocking-antibodies-achieve-primary-endpoints-in-phase-iii-cat-and-birch-allergy-trials 2025-09-09T21:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/cpap-treatment-reduces-mortality-risk-by-26-in-adults-with-type-2-diabetes-and-sleep-apnea 2025-09-09T17:24:10+00:00 hourly 0.9 https://trial.medpath.com/news/rion-spins-out-intent-biologics-to-advance-exosome-based-therapies-for-inflammation-and-immunology 2025-09-09T17:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-centers-pioneer-decentralized-clinical-trial-models-to-expand-patient-access-nationwide 2025-09-09T17:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/bee-sting-inspired-microneedles-deliver-pain-free-drug-therapy-for-neurological-diseases 2025-09-09T17:19:10+00:00 hourly 0.9 https://trial.medpath.com/news/nkgen-biotech-completes-16-9m-acquisition-of-nkmax-gains-control-of-nk-cell-manufacturing 2025-09-09T17:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/immunic-secures-fifth-us-patent-for-multiple-sclerosis-drug-vidofludimus-calcium-extending-protection-through-2041 2025-09-09T17:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/cho-plus-secures-u-s-patent-for-engineered-yeast-cell-technology-to-boost-protein-production 2025-09-09T17:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/kytopen-and-bluewhale-bio-partner-to-accelerate-non-viral-cell-therapy-manufacturing 2025-09-09T17:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/viral-immunotherapy-can-2409-demonstrates-24-5-month-median-survival-in-checkpoint-inhibitor-resistant-nsclc 2025-09-09T17:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/mit-researchers-develop-bottlebrush-polymer-technology-to-dramatically-increase-cancer-drug-payload-delivery 2025-09-09T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/hope-biosciences-stem-cell-therapy-achieves-primary-endpoint-in-phase-2-multiple-sclerosis-trial 2025-09-09T17:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/linusbio-develops-first-hair-based-biomarker-for-als-detection-using-copper-patterns 2025-09-09T17:16:16+00:00 hourly 0.9 https://trial.medpath.com/news/vicero-appoints-dr-han-myint-as-chief-medical-officer-to-advance-vincobody-immunotherapy-pipeline 2025-09-09T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/liscure-biosciences-achieves-world-s-first-fda-ndi-notification-for-hair-health-probiotic-mobiome-r 2025-09-09T17:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/oncoc4-and-biontech-advance-pivotal-phase-3-trial-of-next-generation-ctla-4-antibody-gotistobart-in-squamous-nsclc 2025-09-09T17:15:12+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-acquires-elutia-s-bioenvelope-business-for-88-million-fueling-breast-reconstruction-pipeline 2025-09-09T17:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/insitro-and-eli-lilly-partner-to-develop-ai-powered-admet-prediction-models-for-small-molecule-drug-discovery 2025-09-09T17:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/xtalpi-s-ai-designed-prmt5-inhibitor-pep08-receives-clinical-trial-approvals-for-solid-tumors 2025-09-09T17:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/ionctura-expands-roginolisib-clinical-trials-to-us-market-with-multi-cancer-strategy 2025-09-09T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/cellcentric-completes-enrollment-for-inobrodib-dose-optimization-study-in-multiple-myeloma 2025-09-09T17:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-validates-purist-algorithm-for-personalized-pancreatic-cancer-treatment-selection-in-largest-real-world-study 2025-09-09T17:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/teva-s-emrusolmin-receives-fda-fast-track-designation-for-multiple-system-atrophy-treatment 2025-09-09T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-ns-229-jak1-inhibitor-for-rare-autoimmune-disease-egpa 2025-09-09T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/ridge-biotechnologies-emerges-from-stealth-with-25m-seed-funding-for-ai-driven-enzyme-design-platform 2025-09-09T17:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-inotuzumab-ozogamicin-efficacy-in-indian-patients-with-relapsed-refractory-b-cell-all 2025-09-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-secures-fda-approval-for-phytonadione-injectable-emulsion-in-44-million-market 2025-09-09T13:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/pheon-therapeutics-appoints-google-ventures-dr-samuel-blackman-to-board-as-adc-programs-advance 2025-09-09T13:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/integra-therapeutics-raises-eur10-7-million-to-advance-ficat-gene-writing-platform-and-car-t-therapies 2025-09-09T13:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-scientists-develop-ph-responsive-artificial-cartilage-for-targeted-arthritis-drug-delivery 2025-09-09T13:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-updated-guidance-for-therapeutic-protein-biosimilar-development-with-enhanced-analytical-requirements 2025-09-09T13:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/connecta-therapeutics-advances-first-in-class-neuroplasticity-modulator-cth120-to-phase-ii-for-pediatric-fragile-x-syndrome 2025-09-09T13:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/surgical-resection-combined-with-egfr-tki-shows-promising-results-in-metastatic-nsclc-trial 2025-09-09T13:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-launches-tunelab-ai-platform-to-democratize-drug-discovery-for-biotech-companies 2025-09-09T13:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/mirum-pharmaceuticals-completes-enrollment-in-phase-2b-vistas-study-for-primary-sclerosing-cholangitis-treatment 2025-09-09T13:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/adcs-transform-nsclc-treatment-landscape-with-multiple-fda-approvals-and-expanding-clinical-applications 2025-09-09T10:53:38+00:00 hourly 0.9 https://trial.medpath.com/news/tevogen-s-tvgn-489-t-cell-therapy-achieves-9-11-billion-valuation-following-successful-covid-19-trial 2025-09-09T09:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/matica-biotechnology-partners-with-cirsium-biosciences-to-advance-plant-based-aav-manufacturing-for-gene-therapy 2025-09-09T09:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/alchemab-therapeutics-initiates-phase-1-trial-of-atlx-1282-and-secures-32-million-series-a-extension 2025-09-09T09:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-recruits-former-fda-cell-and-gene-therapy-official-rachael-anatol-to-lead-genetic-medicine-strategy 2025-09-09T09:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/remedium-bio-partners-with-eli-lilly-to-develop-gene-therapies-for-obesity-and-type-2-diabetes 2025-09-09T09:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-acquires-tourmaline-bio-for-1-4-billion-to-advance-anti-inflammatory-cardiovascular-therapy 2025-09-09T09:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-resolves-patent-dispute-with-regeneron-clearing-path-for-eylea-biosimilar-launch-by-2026 2025-09-09T09:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-secures-patent-settlement-with-regeneron-clears-path-for-aflibercept-biosimilar-launch-by-end-of-2026 2025-09-09T09:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/strides-pharma-partners-with-kenox-to-expand-us-nasal-spray-portfolio 2025-09-09T09:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-acquires-tourmaline-bio-for-1-4-billion-to-strengthen-cardiovascular-pipeline-with-pacibekitug 2025-09-09T09:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/synthetic-peptide-pep19-shows-promise-in-reducing-visceral-fat-and-improving-sleep-in-obese-adults 2025-09-09T09:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/tolerance-bio-partners-with-zipcode-bio-to-develop-targeted-thymus-therapeutics-for-immune-aging 2025-09-09T06:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/dianthus-therapeutics-closes-upsized-288-million-public-offering-to-advance-complement-therapeutics-pipeline 2025-09-09T06:45:05+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-reduces-long-covid-risk-by-64-in-overweight-adults-uk-study-finds 2025-09-09T06:42:35+00:00 hourly 0.9 https://trial.medpath.com/news/photonpharma-secures-u-s-patent-for-novel-cancer-immunotherapy-using-photochemically-inactivated-tumor-cells 2025-09-09T06:41:56+00:00 hourly 0.9 https://trial.medpath.com/news/pressure-enabled-drug-delivery-system-enhances-nelitolimod-efficacy-in-liver-tumors 2025-09-09T06:41:26+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-restructures-leadership-team-with-digital-and-transformation-functions-integration 2025-09-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amo-pharma-launches-largest-ever-clinical-trial-for-rare-heart-condition-arvc-with-gsk3b-inhibitor-amo-02 2025-09-09T04:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/four-jak-inhibitors-now-enable-personalized-myelofibrosis-treatment-approaches 2025-09-09T04:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/seladelpar-shows-promise-in-stabilizing-liver-stiffness-in-primary-biliary-cholangitis-patients 2025-09-09T02:46:19+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-expands-global-research-network-with-new-san-diego-institute-and-154m-shanghai-adc-manufacturing-facility 2025-09-09T01:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/sound-wave-innovation-and-sumitomo-heavy-industries-partner-to-advance-lipus-brain-device-for-alzheimer-s-treatment 2025-09-09T01:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/immix-biopharma-secures-strategic-investment-from-goose-capital-for-al-amyloidosis-car-t-therapy 2025-09-09T01:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-bristol-myers-bispecific-antibody-achieves-76-3-response-rate-in-small-cell-lung-cancer-phase-ii-trial 2025-09-08T21:17:24+00:00 hourly 0.9 https://trial.medpath.com/news/uc-san-diego-researchers-develop-non-hormonal-hydrogel-treatment-for-menopausal-vaginal-symptoms 2025-09-08T21:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-shows-dora-insomnia-drugs-have-minimal-abuse-potential-compared-to-traditional-sleep-medications 2025-09-08T21:13:58+00:00 hourly 0.9 https://trial.medpath.com/news/scotland-approves-linzagolix-for-endometriosis-treatment-expanding-access-across-uk 2025-09-08T21:13:53+00:00 hourly 0.9 https://trial.medpath.com/news/aavivo-advances-in-vivo-car-t-platform-with-pace-technology-for-precision-gene-delivery 2025-09-08T21:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/apollo-trial-establishes-new-standard-for-high-risk-acute-promyelocytic-leukemia-treatment 2025-09-08T21:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/phanes-therapeutics-doses-first-biliary-tract-cancer-patient-with-novel-bispecific-antibody-spevatamig 2025-09-08T21:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/dianthus-therapeutics-claseprubart-meets-all-endpoints-in-phase-2-myasthenia-gravis-trial 2025-09-08T21:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-biontech-covid-booster-shows-strong-immune-response-in-late-stage-study 2025-09-08T21:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/azacitidine-ruxolitinib-combination-shows-promise-for-advanced-myeloproliferative-neoplasms 2025-09-08T17:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-and-bristol-myers-squibb-report-promising-phase-2-results-for-pumitamig-in-extensive-stage-small-cell-lung-cancer 2025-09-08T17:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/cs-diagnostics-submits-patent-application-for-cs-protect-hydrogel-organ-spacer-device 2025-09-08T17:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-saol-s-sl1009-treatment-for-rare-pediatric-mitochondrial-disease 2025-09-08T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/kbi-biopharma-partners-with-infinimmune-to-advance-human-first-antibody-manufacturing-for-atopic-dermatitis 2025-09-08T17:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-air-s-neuronos-receives-fda-orphan-drug-designation-for-glioblastoma-therapy-ba-101 2025-09-08T17:12:32+00:00 hourly 0.9 https://trial.medpath.com/news/anktiva-reverses-lymphopenia-and-extends-survival-in-checkpoint-inhibitor-resistant-lung-cancer 2025-09-08T17:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/icecure-s-prosense-cryoablation-system-achieves-superior-results-in-early-stage-breast-cancer-trial 2025-09-08T17:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/cormedix-makes-5-million-strategic-investment-in-talphera-s-phase-3-anticoagulant-program 2025-09-08T17:11:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-clinical-trial-for-pig-kidney-transplants-as-second-patient-achieves-dialysis-free-life 2025-09-08T17:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-3d-printing-glue-gun-for-real-time-bone-graft-surgery 2025-09-08T13:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/atom-therapeutics-urat1-inhibitor-lingdolinurad-meets-primary-endpoint-in-phase-2b-3-chronic-gout-trial 2025-09-08T13:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/hypofractionated-radiotherapy-reduces-treatment-time-and-toxicity-while-maintaining-survival-in-limited-stage-small-cell-lung-cancer 2025-09-08T13:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-first-in-class-allergen-blocking-antibodies-show-52-reduction-in-cat-allergy-symptoms-in-phase-3-trials 2025-09-08T13:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-ea5181-trial-shows-no-survival-benefit-for-concurrent-durvalumab-with-chemoradiotherapy-in-stage-iii-nsclc 2025-09-08T13:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/charm-therapeutics-appoints-dr-erkut-bahceci-as-cmo-to-lead-next-generation-menin-inhibitor-development 2025-09-08T13:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/tigulixostat-shows-superior-efficacy-over-febuxostat-in-phase-2-gout-trial 2025-09-08T13:14:24+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-university-receives-double-digit-million-nih-grant-for-phase-ii-trial-of-tiprelestat-in-pulmonary-arterial-hypertension 2025-09-08T13:14:18+00:00 hourly 0.9 https://trial.medpath.com/news/locate-bio-receives-fda-ide-approval-to-expand-restore-clinical-study-of-ldgraft-bone-graft-substitute-to-us 2025-09-08T13:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/dea-licensing-contradictions-block-fda-approved-cannabis-research-while-va-seeks-foreign-imports 2025-09-08T13:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/nrg-therapeutics-raises-67-million-to-advance-novel-mitochondrial-targeting-therapy-for-parkinson-s-and-als 2025-09-08T13:12:06+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-pointer-trial-demonstrates-lifestyle-interventions-can-prevent-cognitive-decline-in-diverse-populations 2025-09-08T10:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/sirnaomics-secures-hkd-138-million-strategic-investment-from-bloomage-biotech-for-rnai-therapeutics-development 2025-09-08T09:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/toolgen-files-patent-infringement-lawsuit-against-lonza-over-crispr-technology-used-in-casgevy-production 2025-09-08T09:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/servier-acquires-ker-0193-for-450m-to-target-fragile-x-syndrome-marking-first-neurology-asset 2025-09-08T09:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-s-btk-inhibitor-orelabrutinib-gains-singapore-approval-for-relapsed-refractory-marginal-zone-lymphoma 2025-09-08T09:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-fast-track-review-program-for-nicotine-pouches-under-trump-administration-pressure 2025-09-08T09:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/mankind-pharma-receives-cdsco-approval-for-phase-1-trial-of-jak-inhibitor-mkp11093-for-autoimmune-disorders 2025-09-08T09:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/a2-bio-to-present-early-clinical-data-from-logic-gated-car-t-therapy-trials-at-sitc-2025 2025-09-08T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/epigenic-therapeutics-secures-60-million-series-b-to-advance-epigenetic-therapies-for-hepatitis-b-and-cholesterol 2025-09-08T06:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-passes-medicines-amendment-act-to-accelerate-drug-approvals-through-international-recognition 2025-09-08T01:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/aumolertinib-plus-anlotinib-shows-promise-for-untreated-egfr-mutant-nsclc-with-cns-metastases 2025-09-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aspirin-therapy-shows-no-significant-benefit-for-chronic-rhinosinusitis-with-nasal-polyps-in-randomized-trial 2025-09-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-receives-fda-approval-for-eydenzelt-first-aflibercept-biosimilar-for-retinal-diseases 2025-09-07T21:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/precigen-s-papzimeos-becomes-first-fda-approved-treatment-for-rare-respiratory-disease 2025-09-07T21:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-stocks-surge-following-acip-rsv-vaccine-recommendations-and-gilead-pipeline-updates 2025-09-07T17:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/junshi-biosciences-il-17a-inhibitor-js005-meets-primary-endpoints-in-phase-3-psoriasis-trial 2025-09-07T17:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/abbv-706-shows-promising-58-response-rate-in-relapsed-small-cell-lung-cancer-phase-i-trial 2025-09-07T17:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/adjuvant-crizotinib-fails-to-improve-disease-free-survival-in-early-stage-alk-positive-nsclc 2025-09-07T13:13:53+00:00 hourly 0.9 https://trial.medpath.com/news/summit-therapeutics-ivonescimab-shows-regional-efficacy-disparities-in-phase-iii-lung-cancer-trial 2025-09-07T13:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/genesight-pharmacogenomic-test-demonstrates-significant-clinical-benefits-for-major-depressive-disorder-treatment 2025-09-07T03:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-amlitelimab-shows-significant-efficacy-in-phase-3-atopic-dermatitis-trial 2025-09-07T02:40:51+00:00 hourly 0.9 https://trial.medpath.com/news/adagene-s-masked-anti-ctla-4-therapy-adg126-shows-30-response-rate-in-treatment-resistant-colorectal-cancer 2025-09-07T01:15:22+00:00 hourly 0.9 https://trial.medpath.com/news/checkmate-77t-trial-shows-perioperative-nivolumab-preserves-quality-of-life-in-resectable-nsclc 2025-09-07T01:13:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-to-amneal-pharmaceuticals-over-contaminated-iv-bags-in-sterile-injectable-production 2025-09-07T01:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/ai-lung-cancer-risk-model-sybil-validated-in-predominantly-black-patient-population 2025-09-07T01:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/theratechnologies-launches-egrifta-wr-first-weekly-formulation-for-hiv-associated-lipodystrophy 2025-09-07T01:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/h2-global-group-receives-european-regulatory-approval-for-first-hydrogen-inhalation-therapy-trial-in-alzheimer-s-disease 2025-09-06T21:13:55+00:00 hourly 0.9 https://trial.medpath.com/news/sprintray-acquires-envisiontec-dental-portfolio-following-desktop-metal-bankruptcy 2025-09-06T21:11:47+00:00 hourly 0.9 https://trial.medpath.com/news/nuvation-bio-surges-14-9-on-analyst-upgrades-and-oncology-pipeline-progress 2025-09-06T21:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-researchers-advance-cancer-treatment-with-novel-pan-kras-inhibitor-and-precision-therapies 2025-09-06T17:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-cemdisiran-shows-positive-phase-3-results-driving-investment-interest-despite-mixed-market-performance 2025-09-06T17:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/ultrasound-ai-secures-patent-for-ai-driven-clinical-value-determination-from-medical-images 2025-09-06T17:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/hinge-bio-strengthens-leadership-team-and-publishes-promising-data-for-novel-lupus-treatment-hb2198 2025-09-06T17:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/oecd-approves-toxys-toxtracker-for-global-test-guideline-programme-advancing-animal-free-genotoxicity-testing 2025-09-06T17:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-reports-positive-phase-3-results-for-palynziq-in-adolescent-pku-patients 2025-09-06T17:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/lila-biologics-partners-with-eli-lilly-for-ai-driven-radioligand-therapy-development 2025-09-06T09:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/cognivia-s-covariate-adjustment-method-improves-clinical-trial-precision-by-23-4-for-subjective-endpoints 2025-09-06T05:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-vonvendi-approval-to-include-pediatric-von-willebrand-disease-patients 2025-09-06T05:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-digital-pathology-methods-transform-trop2-biomarker-assessment-in-nsclc 2025-09-06T02:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/legend-biotech-explores-dual-listing-strategy-to-accelerate-car-t-therapy-expansion 2025-09-06T01:13:14+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-and-remibrutinib-emerge-as-new-treatment-options-for-chronic-spontaneous-urticaria 2025-09-06T01:11:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-implements-import-alert-to-combat-unsafe-glp-1-drug-ingredient-imports-amid-obesity-treatment-shortage 2025-09-06T01:10:06+00:00 hourly 0.9 https://trial.medpath.com/news/dbv-technologies-launches-150m-atm-program-to-fund-viaskin-peanut-patch-bla-submissions 2025-09-06T01:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/dbv-technologies-establishes-150-million-at-the-market-program-to-fund-viaskin-peanut-patch-development 2025-09-06T01:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/augurex-presents-novel-14-3-3eta-biomarker-data-for-axial-spondyloarthritis-diagnosis-at-acr-convergence-2025 2025-09-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/curapath-and-cayman-chemical-partner-to-expand-global-access-to-peg-free-lipids-for-next-generation-lnp-therapies 2025-09-05T21:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/bevacizumab-erlotinib-combination-shows-remarkable-72-response-rate-in-rare-hlrcc-associated-kidney-cancer 2025-09-05T21:17:39+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-and-phoenix-senolytix-forge-strategic-cross-licensing-agreement-to-advance-injectable-safety-switch-technology-for-cell-and-gene-therapies 2025-09-05T21:16:35+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-licenses-heart-disease-drug-hrs-1893-to-braveheart-bio-for-65m-upfront-potential-1b-total 2025-09-05T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-develop-novel-enpp1-inhibitor-stf-1623-to-transform-cold-tumors-into-immunologically-active-targets 2025-09-05T21:15:15+00:00 hourly 0.9